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ABSTRACT
Since Harman ' fîrst proposed that the mitochondria plays a role in the aging process, several 
lines of research have been undertaken to support his theory. According to the theory, oxygen 
free radicals are responsible for the age-associated decline in function at the cellular, tissue and 
organ levels. The mitochondria use oxygen at a high rate, but due to a dysfunction in its usage of 
oxygen the mitochondria releases oxygen free radicals, which exceeds the cellular antioxidant 
defense. The mitochondrial genome, however, is extremely susceptible to oxidative damage and 
DNA mutations, including deletions when compared to nuclear DNA. One of the causative 
agents of this deletion(s) includes oxygen free radicals, by-product of ATP (energy) production. 
The most frequent deletion associated with aging and diseases is known as “the common 
deletion” or 4977 base pair (bp) deletion. In recent years a number of studies have been able to 
detect mitochondrial DNA (mtDNA) deletions in various tissues from individuals over 20 years 
of age. However, these studies were all cross-sectional in nature and the DNA sources were all 
post-mitotic tissues such as muscle and brain. Mitotic tissues, such as blood were not used even 
though acquiring blood is usually less invasive and would be more convenient to study the aging 
process. Also, since aging occurs over time a longitudinal study design would be the most 
appropriate model for the detection and quantification of mtDNA deletion(s). It has been well 
documented that identical mtDNA is transmitted from mother to child at the point of conception, 
and therefore monitoring the incidence of mtDNA deletion(s) by employing a maternal line 
across several generations would mimic a longitudinal study model. Therefore, the first purpose 
of this study is to mimic the benefits of a longitudinal study design by employing maternal lines 
(3 & 4 generations) to establish mtDNA deletion(s) as a sensitive, specific and stable biomarker 
for studying the aging process. The second purpose of this study is to determine the differences 
in mtDNA deletions when comparing muscle and blood. There were 75 healthy participants with 
age ranging from 8 months to 99 years. The participants provided 71 blood samples and 27
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muscle biopsies. Four participants (two Great grandmother lab #s 9 & 30 and two Daughters: 
lab #s 8 & 63) belonged to more than one generation. Although four individuals were classified 
for more than one generation, their data was entered only once and analyzed accordingly. After 
accounting for the repeated results and the withdrawals there was a total of 80 blood sample 
results and 27 muscle biopsy results. Using the Polymerase Chain Reaction (PCR), mtDNA from 
blood and muscle samples were amplified and the proportion of total and deleted mtDNA 
determined using ethidium bromide staining and a gel electrophoresis analysis system. The 
proportion of deleted mtDNA was compared between different age cohorts and between blood 
and muscle samples using the following statistical methods: i) A one way analysis of variance 
(one way ANOVA) was used to determine the significant difference between the different age 
cohorts and it was observed that the age cohorts differed significantly, ii) Further, a post hoc 
analysis using the Tukey HSD test proved statistical significance for all the age cohorts studied, 
iii) The McNemar Chi-Square was used to determine the significant difference of the proportion 
of deletion for the matched pairs (muscle versus blood) and it was observed that there was no 
significant difference between the blood and muscle samples, iv) In addition, the Kappa Statistic 
was used to evaluate the measure of agreement on the proportion of 4977-bp deletion in blood 
and muscle samples, and it was observed that there was no significant agreement between the two 
samples, v) Further, a Chi-Square test was used to determine the significant difference of the 
proportion of mtDNA deletion from each sample. It was observed that the proportion of deletion 
in blood was statistically significant (p < 0.05) across four (4) age cohorts studied. Also, the 
proportion of deletion in muscle was statistically significant across three (3) age cohorts studied, 
vi) Finally, a post hoc pairwise comparison was used to locate the significant difference (p <
0.05) in each of the chi-square analyses and it was observed that GGM were significantly higher 
(p < 0.05) in the proportion of 4977-bp deletion for blood versus GD and GGC. Similarly, 
daughters (D) were significantly higher (p < 0.05) than their daughters (GD) and their 
granddaughters (GGC). Also in muscle, GGM were significantly lower (p < 0.05) than their
111
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granddaughters (GD) in the proportion of4977-bp deletion. Likewise daughters (D) were 
significantly lower (p < 0.05) than their daughters (GD). No significant difference reported in the 
proportion of deletions between blood and muscle samples would indicate that either blood or 
muscle could be used as a source for the isolation, detection and quantification of mtDNA 
deletions. However, it must be noted that in blood samples there was a trend toward greater 
proportion of deletion as age increased but for muscle samples, the reverse was true. We reported 
for the first time the use of a maternal line model to explain the effects of time on mtDNA 
deletion and aging. In addition, from a technical standpoint, we were able for the first time to 
isolate, elute and quantify mtDNA from both blood and muscle samples that has been isolated, 
eluted and quantified from blood presence that were stored on FTA Cards. Finally, in our 
research we report for the first time the existence of the deletion in all infants in the absence of 
any known mitochondrial disorder suggesting factors other than chronological age may be 
responsible for this deletion.
IV
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INTRODUCTION
Considerable research has been conducted in an attempt to explain the factors that cause aging. 
The multifaceted decline of functions during human aging supports the view that aging is the 
result of multiple underlying causes. One of the most prominent hypothesis employed to explain 
aging is the Error Accumulation Hypothesis, first proposed by Harman in 1956 ' and states that as 
cells age they accumulate errors or mutations, some of which have been identified as 
mitochondrial DNA (mtDNA) deletions. The mitochondrion has been cited as the organelle 
implicated in this accumulation of errors. However, little research has been conducted employing 
a longitudinal study design to support the Error Accumulation Hypothesis and show the 
relationship between the mitochondria and the aging process over time. Also, there has been 
limited work performed on isolating, detecting and quantifying these deletions in a mitotic tissue 
such as blood.
The following introduction will discuss the main function of the mitochondria within the cell, its 
vulnerability, and the main factors resulting in its damage leading to severe consequences for the 
cell. This introduction also looks at the existing research designs and the types of tissue samples 
used for analyzing error accumulations in the mitochondria. In addition, several studies have 
been used to explain the relationship between the mitochondria and the aging process. These 
studies have attempted to explain the mechanism surrounding the Error Accumulation Hypothesis 
and how over time the mitochondria could play a key role in the aging process. This overview 
will also examine the evidence and discuss its application in attempting to elucidate the molecular 
basis of aging.
Aging
Aging is defined as the progressive accumulation of various changes with time both at the 
molecular and cellular levels, resulting in an increased susceptibility of humans to diseases and
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ultimately death.  ̂ However, the exact causes and the molecular mechanisms surrounding the 
aging process remain unclear. Presently, there are three popular hypotheses attempting to explain 
the aging process, all of which seem to have an impact on the mtDNA: There is Programmed Cell 
Death or apoptosis,  ̂which is cellular degradation, initiated by a genetic factor or certain 
chemical or morphological changes within the mitochondria.  ̂ In addition, there is the Telomere 
Hypothesis '* which proposes that DNA sequences within the nucleus of the cell shorten during 
cell division and over time could lead to the loss of functionally important regions, which could 
ultimately affect the mitochondrial genome. * Finally, there is the Error Accumulation 
Hypothesis ', which is the major focus of this review. This hypothesis suggests that the 
mitochondria, because of its constant production of energy in the form of adenosine triphosphate 
(ATP) and a very harmful by-product, oxygen free radicals, the structures within the 
mitochondria are exposed to the harmful effect of the firee radicals.  ̂ Since the mtDNA is located 
in the matrix,  ̂where there is a complex mixture of soluble enzymes in close proximity that 
catalyze the reactions involved in respiration, it becomes highly vulnerable to oxidative damage.  ̂
In addition to mtDNA damage, ultra structural and physiological changes such as swelling and 
rupture of the outer mitochondrial membrane destroy the integrity of the entire mitochondrion. 
7.8.9.10 time, the cells accumulate increasing levels of damage or mutations within 
macromolecules such as proteins, lipids and DNA, ' resulting from continuous exposure to 
oxygen free radicals. Accumulation of these mutations over time diminishes their capacity to 
generate ATP, thereby disrupting cells, tissues and the whole organism’s ability to function 
efficiently. "  Consequently, there is age- associated impairment of cells and tissues resulting in 
aging characteristics, a variety of diseases and subsequent death. Considering the multiple 
factors contributing to the aging process and its complexity, why should a single organelle, the 
mitochondrion, play such an important role in the aging process? The following section will 
address this question.
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The Mitochondrion
Key Function o f Mitochondria
The mitochondrion is the chief site for energy (ATP) production. * It produces 90% of the cell’s 
ATP through the coupling of oxidative phosphorylation to mitochondrial respiration in human 
and other animal cells.  ̂ The driving force for cellular activity is the conversion of chemical bond 
energy to mechanical energy. The most efficient path for ATP regeneration is through 
oxidation of the local stores of glycogen and fat in the body. Built into the folding or cristae of 
the inner mitochondrial membranes are a series of molecules that serve in electron transport 
during oxidation. This electron-transport chain consists of flavoprotein, coenzyme Q and a group 
of iron-containing pigments called cytochromes. These molecules of the electron transport 
system are fixed in position within the inner-mitochondrial membrane in such a way that they can 
collect electrons from reducing agents such as NADH and FADH2 and transport them in a 
defined sequence and direction for the phosphorylation of (adenine di-phosphate) ADP to form 
ATP. ‘‘ At the very last step of this oxidation process, the cytochromes will donate electrons to 
oxygen where the oxygen, an electron acceptor becomes reduced and water is formed.
The Size o f the Mitochondrial Genome
The mitochondria have their own DNA, which generally accounts for less than 1% of the total 
cellular DNA. MtDNA is the only extra-chromosomal DNA in human cells and it exists as a 
16,569-base pair (bp) double-stranded closed circular molecule that is packed into nucleoid 
structures within the matrix,  ̂of the mitochondrion.  ̂ The relatively small size of the 
mitochondrial genome made it possible for it to be sequenced and published in 1981.  ̂ It 
revealed that the entire mitochondrial genome, with the exception of the D-loop, encodes either a 
key respiratory chain protein or a crucial tRNA or rRNA molecule. It further revealed that 
mtDNA carries the information for 37 genes that encodes 22tRNAs, 2rRNAs and 13 subunits of 
the oxidative phosphorylation complex.  ̂ The rRNA and tRNA molecules are used in the
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machinery that synthesizes the 13 polypeptides. * The 13 polypeptides are subunits of the protein 
complexes in the inner mitochondrial membrane, including cytochrome b and subunits of NADH 
dehydrogenase, cytochrome c oxidase, and ATP synthase. * Although the nuclear DNA encodes 
the majority of enzymes involved in oxidative phosphorylation, the 13 sub-units derived from the 
mtDNA are essential for normal electron transport chain activity and ATP production.  ̂
Therefore, a symbiosis exists: the cell is dependent on the mitochondria for energy production, 
and the mitochondria are dependent on the cell for the majority of its structural and enzymatic 
proteins necessary for adequate function. "  The nuclear genome is also involved in the 
regulation of mitochondrial activity, including the expression and replication of mtDNA.
Maternal Inheritance o f mtDNA
Mitochondrial DNA (mtDNA) is inherited maternally, and the DNA transmission from 
mother to child is of high fidelity (Figure A-1, page 65). Through the oocyte cytoplasm, the 
mother transmits her mtDNA to her offspring. The contribution of sperm to the mtDNA in a 
fertilized egg is insignificant. ^  Technically the child should have the identical mtDNA as the 
mother at the time of conception, therefore differences seen in mtDNA deletions within a 
maternal line could be the result of aging or environmental factors. In fact. Parsons et al. 
reported that in the transmission of mtDNA, there is only one base substitution in every 33 (1/33) 
generations.
Susceptibility o f mtDNA
Another feature of the mitochondria that makes it of interest when studying the aging process is 
the fact that its DNA has been shown to be very susceptible to damage. The mtDNA is naked * 
in that unlike nuclear DNA the genome does not bind to histones or other specific DNA-binding 
proteins that normally serve to protect nuclear DNA. As well, it is located near the inner 
membrane of the mitochondria (the matrix), "  which is continually exposed to high levels of
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oxygen free radicals generated through oxidative phosphorylation or extrinsic sources within the 
environment. In addition, the compactness of the mitochondrial genome (no introns or 
intervening sequences between coding regions) increases the possibility that mutation will affect 
functionally important regions. More over, it replicates more frequently than nuclear DNA 
and lacks proof reading or efficient DNA repair systems. However the mitochondrial DNA 
polymerase, the enzyme that replicates mitochondrial DNA (DNA polymerase ganuna) has some 
editing capabilities. ^  This is a common feature of DNA polymerases, which permits them to 
remove incorrect bases that have been added to the strand being synthesized (3’-S’ exonuclease 
activity) and replace them with the correct one. ^  A wide variety of specific oxidative lesions in 
mtDNA (including abasic sites, thymine and cytosine lesions, 8-hydroxy-deoxyguanosine, and 
others) can all be repaired efficiently and therefore, suggests that a base excision repair 
mechanism also operate in the mitochondria. ^  In addition, there appears to be a functional 
alkyltransferase repair pathway within mitochondria. ^  However, there is evidence to suggest 
that the mechanism of nucleotide excision and repair systems which remove dimers do not 
function properly in mitochondria when compared to similar nuclear repair pathways. ^  Even 
with the existing repair mechanisms in operation, there remains a 10-fold greater mutation rate in 
mtDNA than in nuclear DNA, presumably due to the high level of oxidative damage.
Oxygen Free Radical Formation
Like most manufacturing processes, the energy production system in oxidative phosphorylation 
produces toxic waste in the form of reactive intermediate oxygen species or oxygen free radicals, 
which have been shown to be very destructive to the mitochondrion. These intermediates may 
be defined as any species capable of independent existence and possessing one or more unpaired 
electron(s). Approximately 2-5% of the molecular oxygen that enters the mitochondria is 
thought to escape complete reduction to water. This reduction process has been calculated to 
account for 95 to 98% of the total oxygen consumption without any oxygen intermediates being
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produced. This small fraction (2 to 5%) of the oxygen consumed by cells, can be utilized in an 
alternative univalent pathway for the reduction of oxygen in which oxygen free radicals are 
produced. "  Some examples of free radicals, which exist in the mitochondria are the hydroxyl 
(OFT) ion, superoxide anion (0% , an oxygen-centered radical), peroxyl (RO2", radical 
intermediates arising as a result of lipid oxidation), and nitric oxide (N0~). In addition, some 
nonradical oxygen-derived species are hypochlorous acid (HOCL), hydrogen peroxide (H2O2), 
singlet oxygen ÇO2), and ozone ( O 4 ) .  When these molecules are generated in cells, they 
aggressively attack and degrade nucleic acids as well as a variety of membranous structures, 
and many other molecules. ^  Among all the reactive species, the hydroxyl radical may be 
formed either through reduction in the iron catalyzed Fenton reaction or through Haber-Weiss 
reaction. This free radical is the most reactive chemical species in the biological world. To 
counter the negative impact of the reactive species, living organisms have developed a 
sophisticated antioxidant system to cope with oxygen free radical generation. ^  The antioxidant 
system includes chemical compounds such as vitamin E and C, C arotene, and glutathione, as 
well as a series of enzymes specializing in the removal of these free radicals from the body or 
reducing them to more stable species. There is, however, a subtle balance, which exists 
between the generation of free radicals and the ability of the antioxidant system to manage.
When factors such as, chronological age, tobacco smoke and environmental toxins shift the 
balance in favor of excess free radical generation, it leads to deletions occurring in mtDNA.
Age Association with the “common deletion"
The most prevalent deletion associated with aging has been shown to be the 4977-bp deletion or 
the common deletion. It was demonstrated to span 4977-bp with 13-bp repeats located at both 
ends of the 8470 and 13,447 nucleotide positions (np) which are presumable hotspots for the 
generation of the deletion, and is detected predominantly in elderly humans.
Hayakawa et al. suggested that the proportion of mtDNA deletion is increased exponentially
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with age, estimating that the increase could be as high as a 1000. In addition, multiple mtDNA 
deletions have been detected and the number of deletions in individuals over 70 has been reported 
to be significantly higher than those under the age of 40 years. ^  Several other researchers 
have investigated the age association with the common deletion, observing the 4977-bp deletion 
in the brain tissue of two older yet normal subjects. Similarly, Cortopassi and Amheim ™ 
demonstrated that brain and heart mtDNA of normal adults over age 21 contained very low levels 
of the 4977-bp deletion, but importantly, the amount of deleted mtDNA increased with age.
Later, Yen et al. reported the 4977-bp deletion in the liver mtDNA of normal human subjects in 
their mid 30’s. In support of these results, Corral-Debrinski et al. revealed that the 4977-bp 
deletion started to appear in human heart tissue at age 40. Further evidence to support the 4977- 
bp deletion as an aging deletion was the presence of the deletion in various tissues of individuals 
over 40 years of age. The deletion was also shown to increase with age in skeletal muscle 
52.S3.54.55 vaiious Other tissues but was undetectable in fetal tissues such as heart and 
brain. A more recent investigation conducted by von Wurmb et al. reported no deletion 
specific fragments in fetal blood or in individuals under 20 years old. It is interesting to note that 
the age onset of the mtDNA deletions varied greatly with individuals in that a specific type of 
deletion may appear quite early in some individuals, but does not occur in others until very late in 
life. ”  The variability observed in the 4977-bp deletion suggests that a longitudinal study or a 
similar design is necessary to study mtDNA deletion over time. As can be seen in research 
conducted by Wei a cross sectional study approach does not effectively account for the 
variability that is prevalent in mtDNA deletions among different individuals.
Disease Association with the “common deletion”
In addition to the common deletion, there have been more than 80 large-scale deletions identified 
in various tissues of humans and these deletions have been linked to specific mitochondrial 
diseases. Although the concept of mitochondrial disease(s) was first introduced ^  as early as
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1962, it was only in 1988 that two pioneering reports showed an association of mtDNA mutations 
with encephalomyopathies. In recent years a variety of chronic degenerative diseases that 
involve brain, heart, muscle, kidney and endocrine glands have been shown to result from 
mutations in mtDNA. The first pathogenic mtDNA mutations identified were associated with 
rare syndromes such as Leber’s Hereditary Optic Neuropathy (LHON), Myoclonic Epilepsy, 
Ragged-Red Fiber disease (MERRF), Keams-Sayre Syndrome (KSS) and. Chronic Progressive 
External Ophtalmoplegia (CPEG). In addition, to the diseases associated with mtDNA 
deletion(s), mitochondria have also been shown to induce apoptosis ^  and play a non-specific 
role in some carcinogenic processes. Since there is a clear link between mitochondrial 
dysfunction, specific human diseases and apoptosis, the relatively small size of the mitochondrial 
genome becomes an attractive target for genetic analysis. ^
A poptosis
The association between aging and apoptosis marks one of the most important recent 
developments in aging research. Apoptosis, or programmed cell death, is another prominent 
hypothesis used to better explain the aging process  ̂and it suggests that mitochondria play a 
central role in the regulation of apoptosis. Similar to the Error Accumulation Hypothesis, 
apoptosis results in an age- associated impairment of cells and tissues resulting in aging 
characteristics, a variety of diseases and subsequent death. The two hypotheses are not 
mutually exclusive, but rather complementary. In apoptosis, this form of cellular destruction is 
characterized by specific morphologic and biochemical changes ^  such as the degradation of 
chromatin. This degradation of materials in the mitochondrion over time will diminish its 
capacity to generate ATP, thereby disrupting cells, tissues and the whole organism’s ability to 
function efficiently. "  In support of the role of the mitochondria in apoptosis, several major 
arguments have been presented that implicates the mitochondria as playing a major role in the 
process of apoptosis:
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• The mitochondria undergo major changes in membrane integrity as a result of mtDNA 
deletion. These changes include swelling and rupture of the outer mitochondrial membrane 
and the subsequent release of pre-apoptotic proteins including cytochrome C (a key 
component in the induction of apoptosis) “ . The release of mitochondrial cytochrome c leads 
to the cytosolic assembly of the apoptosome-a caspase activation complex involving 
apoptosis protease-activating factors (APAF) and caspase-9 which are both required for the 
activation of caspases and endonucleases in the apoptotic process. ^  (Caspases are a family 
of cysteine proteases implicated in biochemical and morphological changes in cells).
• Also, the mitochondria have large multi-conductance channels (permeability transition [PT] 
pores) that play a role in apoptosis. These PT pores are multi-protein complexes that 
participate in a variety of functions particularly the regulation of transmembrane potential (a 
proton gradient across the inner mitochondrial membrane generated during electron transport 
and ATP production). In addition, the anti-apoptotic oncoprotein Bcl-2 (a nuclear encoded 
mitochondrial protein) stabilizes mitochondrial membrane integrity and prevents opening 
of the PT pore. Changes in membrane integrity and the PT pores cause the disruption of the 
mitochondrial inner transmembrane potential leading to subsequent decrease in ATP 
production, cellular dysfunction and subsequent death.
• Finally, oxidative stress imposed on cells as a result of oxidative phosphorylation can have a 
profound effect on the onset or progression of apoptosis. Intriguingly, apoptosis induced 
by hydrogen peroxide formed during oxidative stress can be stopped or reversed by over 
expression of Bcl-2 “  ® leading to the depletion of the Bcl-2 and the loss of anti-apoptotic 
capabilities within the mitochondrion.
Mitochondrial involvement is probably not required for apoptosis, however, mitochondrial 
processes may be important in the apoptotic pathway. The above arguments have proven to be 
quite compelling in supporting the role of the mitochondria as critical to the aging process.
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Blood and the “Common Deletion”
It was once believed that blood cells, like fetal cells, do not survive long enough to accumulate 
mtDNA mutations, and for this reason blood samples have often been used as a negative control.
Since blood cells from patients with mitochondrial abnormalities show rather low levels of 
mutated mtDNA, it has been proposed that fiequent cell division in hematopoetic precursors 
select against the survival of cells containing defective mitochondria. This intra cellular 
selection cannot take place in post-mitotic tissues like muscle and nerve and hence the high 
deletion rates in post-mitotic tissues. However, arguing against the occurrence of 4977-bp 
deletion exclusively in post-mitotic cells is the observation that more than 99% of peripheral 
blood lymphocytes subsist in the Go phase which would imply that the deletion could be easily 
detected in blood. Further, it has been demonstrated recently, that about 40% of circulating 
lymphocytes have a life span that exceeds 6 months, and some even persist for over 30 years. ” 
As a consequence there is enough time for these cells to accumulate mitochondrial alterations, 
which should be detectable using sensitive PCR techniques. In addition, there is evidence that 
cells containing deleted or mutant mtDNA replicate efficiently and the cellular selection favoring 
the normal or wild type mtDNA may not be a rapid process. “  The mutant mtDNA is smaller 
than the wild type mtDNA so it replicates faster, hence the advantage. “  In addition, the ratio of 
mtDNA in both the wild type and the mutant type (heteroplasmy) will affect the functional ability 
of the cell. “
In an attempt to explain the association between specific tissues and their accumulation of the 
4977-bp deletion, researchers have been able to demonstrate the presence of the 4977-bp deletion 
in well-differentiated tissues such as muscle and brain of older adults. Small amounts of 
this deletion have also been detected in mitotic tissue such as the blood of patients with certain 
disease conditions. With further research von Wurmb et al. detected the 4977-bp 
deletion in blood of healthy persons. Prior to this research Gattermann et al. “  was the only
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group to detect deletion-specific fragments in some blood and bone marrow samples of 
hematologically normal patients by using nested Polymerase Chain Reaction (PCR). In contrast, 
using an automated detection system (fluorogenic probes labeled with fluorescent dyes) were 
unable to demonstrate any accumulation of the 4977-bp deletion with increasing age in whole 
venous blood, isolated human platelets and peripheral blood mononuclear cells, as was observed 
for several other tissues. ”  Therefore, the combination of limited research and conflicting results 
necessitated a study to address the question whether blood could be used to detect the 4977-bp 
deletion associated with aging. This is relevant as the acquisition of blood samples is less 
invasive and may serve as a reliable source for the study of the 4977-bp deletion with age. Also, 
developments in DNA analysis technologies such as PCR, using a more sensitive polymerase 
(Deep-Vent [exo-] DNA Polymerase) and a staining technique (ethidium bromide) along with 
more accurate detection systems (digital gel electrophoresis analysis) may make it much easier 
and more accurate to isolate and detect mtDNA deletion in mitotic tissues.
Research Design and the "Common Deletion”
Previously, researchers have used cross-sectional studies to examine the effect of time on mtDNA 
deletion. However, since aging occurs over time, a longitudinal study design would be more 
effective in examining the efiects of chronological age on mtDNA deletion and aging. It has 
been well documented that identical mtDNA is transmitted maternally via germ cells at the point 
of conception and research evidence supports somatic expression of mtDNA deletion ^  that 
is, mtDNA deletion are not transmitted via germ cells. This would imply that any mtDNA 
deletion seen in an individual would be a result of aging or environmental factors and not as a 
result of germ line mutation. Therefore, a research study using a maternal line extending over 3 
or 4 generations would mimic the strengths of a longitudinal study design and overcome the 
limitations of cross sectional studies and more accurately determine the effects of time on
11
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
mtDNA deletion. Only a few studies, have used this approach to examine the 4977-bp deletion 
and aging.
Statement of the Problem
As revealed by the research literature there is an association between chronological age and the 
4977-bp age associated mtDNA deletion. Also there is little doubt that the mitochondria play a 
pivotal role in the aging process. However, few, have examined mtDNA deletion overtime using 
maternal lines across different generations nor have they been able to detect mtDNA deletions in 
healthy individuals under the age of 20 years. Therefore, the first purpose of this study is to 
mimic the benefits of a longitudinal study design by employing maternal lines (3 or 4 
generations) to establish mtDNA deletion(s) as a sensitive, specific and stable biomarker for 
studying the aging process, providing evidence to substantiate the Error Accumulation 
Hypothesis. Several researchers have demonstrated that mtDNA deletion(s) can be detected in 
muscle, a post-mitotic tissue using improved DNA analysis techniques, but only a few attempts 
have been made to isolate, detect and quantify mtDNA deletion(s) from blood, a more convenient 
mitotic tissue. Thus, the second purpose of this study is to determine the differences in mtDNA 
deletions when comparing muscle and blood.
Hvpotheses
There are four null hypotheses in this study; the first (Ho,) null hypothesis states that the four age 
cohorts are similar and the second (Ho 2) null hypothesis states that the proportion of 4977-bp 
deletion in a sample of blood will be equal to the proportion of 4977-bp deletion in a sample of 
muscle. The third (Ho 3 )  null hypothesis states that the proportion of 4977-bp deletion in a sample 
of blood across four (4) age cohorts of i) Great grandmother (COM), ii) Daughter (D), iii) Grand 
daughter (GD) and iv) Great grandchild (GGC) is equal and the fourth (Ho 4 )  null hypothesis
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States that the proportion of 4977-bp deletion in a sample of muscle across three (3) age cohorts 
of i) GGM, ii) D and iii) GD is equal.
METHODS
Participants
This study investigated the maternal line of 21 families (GGM, D, GD and GGC) each consisting 
of between three and foiu- generations with only the last generation comprising males. There 
were 75 healthy participants ranging in age from 8 months to 99 years. The group provided 71 
blood samples and 27 muscle biopsies (Figure A-2, page 66). Four participants (two Great 
grandmother lab #s 9 & 30 and two Daughters: lab #s 8 & 63) belonged to more than one 
generation. Although four individuals were classified for more than one generation, their data 
was entered only once and analyzed accordingly. After accounting for the repeated results and 
the withdrawals there was a total of 80 blood sample results and 27 of muscle biopsy results 
(Table I).
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Table 1. Descriptive data on participants donating muscle and blood samples'" (1-30)




01 GGC 24 1/85 Y Y
01 GD 49 2/86 Y Y
01 D 69 3/87 Y Y
01 GGM 91 4 N Y
03 GGC 4 5 N Y
03 GGC 13 6 N Y
03 GD 30 7/88 Y Y
03 D 49 8/89 Y Y
03 GGM 69 9 N Y
04 GGC 2 10 N Y
04 GD 42 11/90 Y Y
04 D 69 12/91 Y Y
04 GGM 91 13/92 Y Y
05 GGC 5 14 N Y
05 GD 24 15/93 Y Y
05 D 52 16/94 Y Y
05 GGM 74 17/95 Y Y
06 GGC 5 18 N Y
06 GD 35 19/96 Y Y
06 D 63 20/97 Y Y
06 GGM 83 21/98 Y Y
07 GGC 8 months 22 N Y
07 GD 19 23/99 Y Y
07 GD 19 24/100 Y Y
07 D 42 25/101 Y Y
07 GGM 73 26/102 Y Y
08 GGC 9 27 N Y
08 GD 36 28 N Y
08 D 58 29/103 Y Y
08 GGM 80 30 N Y
14
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Table 1. (Continued) Descriptive data on participants donating muscle
and blood samples” (31-57)
Family number Generation Age (years) ® Lab number Tissue
Muscle Blood
09 GGC 3 31 N Y
09 GD 38 32/104 Y Y
09 D 63 33/105 Y Y
09 GGM 99 34/106 Y Y
10 GD 18 35 N Y
10 D 38 36 N Y
10 GGM 69 37 N Y
11 GGC 3 38 N Y
11 GD 26 39/107 Y Y
11 D 47 40/108 Y Y
11 GGM 76 41/109 Y Y
12 GD 24 42/110 Y Y
12 D 49 43 Y Y
12 GGM 69 44 N Y
13 GGC 10 months 45 N Y
13 GD 28 46 N Y
13 GD 31 47 N Y
13 D 48 48 N Y





15 GGC 15 54 N Y
15 GD 33 55 N Y
15 D 59 56/111 Y Y
15 GGM 80 57 N Y
15
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Table 1. (Continued) Descriptive data on participants donating muscle
and blood samples” (58-84)




16 GD 30 58 N Y
16 D 53 59 N Y
16 GGM 78 60 N Y
17 GGC 5 61 N Y
17 GD 24 62 N Y
17 D 49 63 N Y
17 GGM 69 64 N Y
18 GGC 4 65 N Y
18 GD 26 6 6 N Y
18 D 49 67 N Y
18 GGM 69 6 8 N Y
19 GD 2 0 69 N Y
19 D 36 70 N Y
19 GGM 69 71 N Y
2 0 GGC 1 0  months 72 N Y
2 0 GD 2 0 73 N Y
2 0 D 44 74 N Y
2 0 GGM 62 75 N Y
2 1 GGC 29 76 N Y
2 1 GD 49 77 N Y
2 1 D 6 8 78 N Y
2 2 GGC 23 79 N Y
2 2 GD 58 80 N Y
2 2 D 82 81 N Y
23 GGC 8 82 N Y
23 GD 46 83 N Y
23 D 6 6 84 N Y
”GGM = Great grandmother, D = Daughter, GD = Granddaughter, GGC = Great grandchild. 
""Unless indicated explicitly otherwise Y = present and N = absent
This study received the approval of the Lakehead University Ethics Committee and all the 
participants signed an informed consent (Appendices C-1 and C-2). Also each participant 
completed the Canadian National Public Health Survey and the results obtained from the
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survey were used to exclude individuals who were highly trained endurance athletes and those 
suffering from chronic, systemic or degenerative disorders (Appendix C-3). In addition, a 
selection criterion (Appendix C-4) was designed to exclude any participants that might have any 
factors other than chronological age that could have influenced the quantity of deleted mtDNA.
Procedure 
Sample Collection
A blood sample (< 1ml) was collected from each of the participants (Appendix B-1). The 
samples were obtained from a finger prick and stored on a FTA Card™ (Life Technologies) 
following the manufacturer's instructions (Appendix B-3). Also, approximately 5-25mg of 
muscle biopsy tissue ^  was taken from the vastus lateralis muscle of 27 out of the 71 participants 
and stored at -80°C for subsequent use (Figure A-3, page 67). See (Appendices B-2 and B-3).
DNA Preparation
The muscle biopsy tissue was homogenized and emulsifred in a buffer solution (600 mM NaCl, 
15mM Tris, pH 7.5) and a 100 pJ of the total volume applied to each circle on a labeled FTA 
Card™ (Life Technologies) following the manufacturer’s instructions. At the time of 
homogenization all fat and connective tissue were removed from the samples and each sample 
was weighed. To remove blood, the muscle samples were washed several times in Tris buffer 
(pH 7.5). Following the wash, the samples were minced with a scalpel and brought up to 20 
volumes with respect to their original weight. The muscle samples were homogenized on ice 
using a disposable hand held homogenizer (1.5 ml Disposable Pellet Pestle), [Kimble/Kontes, 
Vineland, New Jersey USA]. Total DNA (nuclear and mitochondrial) was extracted from both 
the blood and muscle samples using the FTA purification Protocol (Life Technologies) according 
to the manufacturer’s instructions. Total DNA was then eluted from the FTA Card™ (following
17
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modifications to the manufacturer’s instructions) by adding lOOpJ of TE to the tubes containing 2 
to 3 purified paper punches and the samples incubated at 4°C for 24hrs. The concentration of 
total DNA in each sample was determined by spectrophotometry (GeneQuant IIRNA/DNA 
Calculator, Pharmacia Biotech [Biochrom] Ltd., Cambridge, England) and then adjusted to I 
ng/p.1 (Appendix B-4).
Oligonucleotides, Standards and Controls
HPLC purified oligonucleotide primers were chemically synthesized by Operon Technologies, 
Inc. (Almeda, Ca), using nucleotide sequences obtained from the literature.  ̂ The sequences of 
the synthesized oligonucleotides and the sizes of PGR products amplified are shown in Table 2.
In addition to negative controls (TE buffer; 10 mM Tris-HCl, pH 8.0, 0.1 mM EDTA) that was 
used in the DNA purification and elution stages), our PCR analysis for mtDNA deletions always 
included positive controls (DNA from a patient known to carry the common deletion). The size 
standard pBR322 DNA- Msp 1 Digest (New England BioLabs Inc.) was used to determine the 
location of the DNA band of interest and also as a reference during the quantification phase.
Table 2. Oligonucleotide primers used for PCR amplification of the 4977-bp deleted
mtDNA and total mtDNA
Primer pair_________________Amplified Position 5'- 3'__________The length of amplified product (bp)
T,T2 1257 - 1433 177
DiDz”_____________________8416- 13519___________________ 127____________________________
T, (1257 - 1279) 5 -TATACCGCCATCTTCAGCAAAC-3'
Tz (1433 - 1411) 5 -TACTGCTAAATCCACCTTCGAC-3'
D, (8416 - 8437) 5 -CCTTACACTATTCCTCATCACC-3 '
Dz (13519 - 13498) 5 -TGTGGTCnTGGAGTAGAAACC-3'_____________________________________
* The primer set T 1T2 was used for the determination of total mtDNA 
” The primer set D1D2 was used for the determination of deleted mtDNA
The primer pair (T,: nucleotide position 1257 and T2: nucleotide position 1433) were used to
amplify the 177-bp fragment from the 12s region, a highly conserved area  ̂of the mitochondrial
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genome which is known to be free of mutations, specifically deletions, and therefore should 
always be present for detection and amplification. This was used to represent total mtDNA or a 
positive control. The primer pair (D,: nucleotide position 8416 and Dz: nucleotide position 
13519) was used to amplify the deletion-specific 127-bp fragment from a conserved region * 
flanking the 4977-bp deletion indicating the presence of the 4977-bp mtDNA deletion (Figure A- 
4, page 6 8 ).
Polymerase Chain Reaction (PCR)
Two separate PCR’s were performed on each sample, amplifying the two desired sets of DNA 
fragments. Each PCR reaction was performed in a 25 pJ reaction mixture containing; template 
DNA, one pair of primers (T1T2 or D 1D2) and each deoxyribonucleoside triphosphate (dNTP), 
MgS0 4 , thermopol reaction buffer, Deep-Vent (exo-) DNA Polymerase and Bovine Serum 
Albumin (BSA) all obtained from New England BioLabs Inc. The volume and concentration of 
the template DNA, primers, dNTPs, MgS0 4 , buffer, polymerase and BSA are listed in Table 3.
Table 3. The volume and concentration of the different reagents 
required for a 25 jil PCR reaction mixture.






Buffer lOX IX 2.5 pi
M g S 0 4 100 mM lX(2mM ) 0.5 pj
BSA lOX IX 0.25 pi
dNTPs lOOX(lOOmM) IX (1 mM) 0.25 pi
Polymerase 2000 U/ml 0.5 units 0.25 pi
Primers 20 pM 0.2 pM 0.5 pi
ddH2 0 N/A N/A 15.75 pi
Template DNA Ing 5.0 pi
Total 25 pi
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Samples were amplified in a PTC-225 DNA Engine Tetrad Thermocycler (MJ Research, Inc., 
Waltham, Massachusetts). The first cycle consisted of a hot start at 95“C for 5 min followed by 
30 cycles consisting of a dénaturation step at 94°C for 30s, annealing at 60°C for I min, and 
primer extension at 72°C for 30 sec, with a final extension for 10 min at 72°C (Appendix B-5).
Polymerase Sensitivity
Mitochondrial DNA comprises less than 1% of the total DNA and the highest mean 
concentration of any particular mutation such as the 4977-bp deletion may be maximally about 1 
% in any particular tissue homogenate. ^  Therefore, the amplification of any fragment of the 
mtDNA representing the 4977-bp deletion will require a very sensitive PCR polymerase. Deep- 
Vent (exo-) DNA Polymerase was chosen because when compared with other polymerases, it was 
more sensitive in detecting low concentrations (as low as 10 fg) of DNA firagments. “  According 
to Hilali et al. the use of this Polymerase might prove to be a universal PCR method in 
amplifying very low levels of DNA.
Detection System
Following amplification, for each participant, 4^1 of the total and 4pl of the deleted PCR product 
(alternating between total and deleted samples) were loaded in separate lanes on the same gel (6 % 
polyacrylamide gel). Also, 4^1 of the size/reference standard (pBR322 DNA- Msp 1 Digest) and 
4pJ of the appropriate control were loaded in separate lanes. The gel was allowed to run at 140V, 
500mA for 45 min (Appendix B-6 ). After separation, the DNA bands were visualized by 
transillumination under UV light after staining with ethidium bromide [50pg/ml], (Figure A-5, 
page 69). See (Appendix B-7).
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Quantification o f DNA Bands
Quantification of amplification products was performed using the Kodak Electrophoresis 
Documentation and Analysis System [EDAS] (Eastman Kodak Company, Rochester, NY) and 
image analysis software (Kodak ID Image Analysis Software). Each gel contained 4pl of the 
size standard pBR322 DNA- Msp 1 Digest, at a concentration of 400ng. The standard produces 
16 bands ranging from 76-bp to 622-bp. When calculating the band mass of each sample, the 
software determines total area (the leading and trailing edges) of each band and then sums the 
intensity of each pixel within the band rectangle (Appendix B-7). During these calculations, the 
software determines the intensity of the background of the image and adjusts the results to 
calculate the true band intensity. Using the band intensity measured for each standard band in the 
standard lane, ID analysis software models the data using different functional forms: power, 
exponential.2“* and 3"* order polynomials to generate a fitted curve (Figure 1).
Figure 1. A standard fitted curve of the mass versus the net intensity of each standard band 
generated by the Kodak ID Image Analysis Software (Eastman Kodak Company, 
Rochester, NY)
To determine the mass in nanograms (ng) of total and deleted bands in each sample the true band 
intensity for each sample is ploned against the standard fitted curve. The 177-bp fragment from 
the highly conserved region of the mitochondrial genome was used to represent total mtDNA,
2 1
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whereas the 127-bp fragment represented deleted mtDNA (4977-bp). Following this, a ratio 
(mass of deleted fragment divided by mass of total fragment) was determined for each sample.
To avoid false positive results and address the issue of template or reagent contamination, each 
PCR reagent along with blank FTA Card punches and negative controls (TE: 10 mM Tris-HCl, 
pH 8.0,0.1 mM EDTA) were simultaneously processed along side FTA Card punches containing 
sample. In addition, selected firagments of the 12s region (highly conserved region of mtDNA) 
and the Hypervariable Region 2, (HV2) of the template mtDNA were sequenced (ABI Prism 310 
Genetic Analyzer, PE Applied Biosystems, Foster City California) to confirm the presence of 
single template DNA and to establish a maternal line relationship. The results suggested that 
each sample contained only single template DNA indicating that there was no contamination and 
the 12s and HV2 regions of the mtDNA of all the members in each maternal line were identical, 
indicating that members within each maternal line were clearly related. Finally, to address the 
issue of reproducibility the entire methodology was repeated several times under the same 
conditions and the results were the same (Appendix B-9).
Statistical Analysis
The statistical analysis was conducted using the following six step process: 
i) Since each age cohort represented a generation a one way analysis of variance (ANOVA) was 
used to determine the significant difference between the different age cohorts, ii) Further, to 
determine the source of the significant difference between the age cohorts a post hoc Tukey HSD 
test was used, iii) Considering that we sampled both blood and muscle from each patient, the 
McNemar Chi-Square test was used to determine the significance of the difference for the 
matched pairs (muscle versus blood), iv) In addition, the kappa statistic, described by Montelpare 
and McPherson was used to determine the extent to which muscle and blood samples were 
similar or in agreement, v) A chi square test was used to determine the significance of proportion 
from several independent samples (blood and muscle) in different age cohorts. This technique
2 2
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was described by Fleiss ^and is commonly used to evaluate designs in which proportion of 
events comprise the data, vi) Finally a post hoc pairwise comparison was used to locate the cause 
of the significant difference within each chi-square for blood and muscle samples. Additional 
material further outlining the methodology used in this research is shown in (Appendix B).
RESULTS
In this study, the use of a unique research design, optimization of the PCR protocol, [using longer 
primers, a more sensitive polymerase (Deep-Vent [exo-] DNA Polymerase) and targeting shorter 
amplification fragments], we were able to effectively determine the proportion of the 4977-bp 
deletion in both blood and muscle samples from participants of different age cohorts, some as 
young as 8 -months old. Moreover, the fact that each child in the study presented the deletion was 
significant and totally unexpected. The detection of this deletion may be partly explained by the 
method used to isolate, elute and quantify mtDNA from blood and muscle samples stored on FTA 
Cards. In addition, the high sensitivity of Deep-Vent [exo-] DNA Polymerase and its ability to 
detect DNA template at very low template concentration may have played a critical role in the 
ability to amplify the 4977-bp deletion in blood samples.
Further, we employed a maternal line for the first time to mimic a longitudinal study design and 
effectively investigate the effect of chronological age on mtDNA deletion. This unique research 
design consisted of four (4) age cohorts [Great Grand mother (GGM), Daughter (D), 
Granddaughter (GD) and Great grandchild (GGC)]. Each age cohort was revealed to be 
statistically significant (p < 0.05) from each other. Our results demonstrated that in blood 
samples there was an increased proportion of deletion as age increases, but for muscle samples, 
the reverse was true. We believe that the combination of an improved methodology and the use 
of a maternal line model enabled us to present some of the most relevant findings to date
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attempting to explain the role of the 4977-bp deletion in the aging process. The results are 
outlined in the following section.
Statistical Significance between Age Cohorts
The 21 maternal lines provided a fairly large sample size (n = 7I) and a wide distribution of ages 
across the cohorts (Table 4). The age ranged from 8  months old to 99 years old and enabled us to 
successfully investigate the effects of time on mtDNA deletion extending almost ten decades.
Table 4. Distribution of ages (years)"* among generations included in the study*
Variable GGM D GD GGC
Mean 79.6 52.2 31.5 8 . 6
Minimum 62 36 19 1
Maximum 99 82 58 29
Standard deviation 1 0 . 8 9.6 I I .1 8.7
Sample size 18 2 1 23 18
*GGM = Great grandmother, D = Daughter, GD = Granddaughter, GGC = Great grandchild. 
""Unless indicated explicitly otherwise
Since the maternal line design was based primarily on the analysis of mtDNA deletion across four 
age cohorts it was necessary to ensure that all the age cohorts were significantly different from 
each other. Therefore a one way analysis of variance (one way ANOVA) was used to test for 
significance. The results of the analysis of the one way ANOVA shown in Table 5 indicated that 
there was significance difference (p < 0.05) across the foiu* age cohorts studied.
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Table 5. ANOVA summary for the different age cohorts
ANOVA Summary Table
Source SS df MS F
Between-Group 40670.37 3 13556.79 133.3
Within-Group 6815.33 67 101.72
Total 47485.7 70
*/» <0.05 F = 133 J Critical Value -  2.51
For there to be statistical significance the F value must be greater the critical value
To test for significant difference across the different age cohorts a post hoc Tukey HSD test was 
used to locate the source of significant difference. The results shown in Table 6  indicated that all 
the age cohorts were significantly different (p < 0.05) from each other.
Table 6 . Summary of the Tukey HSD Post Hoc Test
Comparison of Mean Comparison of Mean Mean Difference
Gen I vs. Gen 2 79.64-52.20 27.40 ♦
Gen I vs. Gen 3 79.64-31.57 48.07 *
Gen 1 vs. Gen 4 79.64-8.60 71.04*
Gen 2 vs. Gens 52.20 -  31.57 20.63 *
Gen 2 vs. Gen 4 52.20-8.60 43.60*
Gen 3 vs. Gen 4 31.57-8.60 22.97 *
♦/» <0.05 HSD = 11J7
Any between-group differences that exceeded HSD 11.37 are significant
The proportion of deleted mtDNA in 71 blood samples and 27 muscle samples are reported in 
Table 7. However, there were four instances (two Great grandmother; lab #s 9 &30 and two 
Daughters: lab #s 8  & 63) where participants belonged to more than one generation. These 
samples were not reanalyzed statistically; instead the original results were presented according to
25
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the number of generations that they were a part of. After accounting for the repeated results and 
the withdrawals there was a total of 80 blood sample results and 27 of muscle biopsy results.
26
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Electrophoretogram o f PCR Products
Following amplification, for each participant’s sample (blood and muscle), 4pl of the total and 
4|xl of the deleted PCR product (alternating between total and deleted samples) were loaded in 
separate lanes on the same gel (6% polyacrylamide gel). Also, 4pl of the size/reference standard 
(pBR322 DNA- Msp 1 Digest) and 4^1 of the appropriate controls were loaded in separate lanes. 
The results of six participants in the study are illustrated in Figure 2. The ratio of total mtDNA 
and deleted mtDNA provides a proportion of deleted mtDNA displayed in Table 7.
Figure 2. Electrophoretogram of PCR products. Detection of two different amplification
fragments (Total mtDNA = 177-bp) and Deleted mtDNA = 127-bp) in total mtDNA from human 
blood using polyacrylamide gel electrophoresis (PAGE) following ethidium bromide staining. 
Amplification was carried out using 1 ng of template DNA (nuclear and mitochondrial DNA) 
from 6 individuals for 30 cycles. An aliquot of 4 pi of amplified products were separated on 
polyacrylamide gel and stained with ethidium bromide stain. Lane 1: 177-bp fiagment (primer 
pair T 1/T2) from participant # 1, Lane 2: 127-bp fragment (primer pair D1/D2) from participant # 
1, up to Lane 11: 177-bp fragment (primer pair T 1/T2) from participant # 6 and Lane 12:127-bp 
fragment (primer pair D1/D2) from participant # 6. Lane 13: negative control for PCR master mix 
and (primer pair T 1/T2), Lane 14: negative control for PCR master mix and (primer pair D1/D2). 
Size standard was 4 pi of pBR322 DNA- Msp 1 Digest, at a concentration of 400ng, with 16 
bands ranging from 622-bp to 76-bp visible in order from the top to bottom respectively of lane 
15.
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Table 7. The proportion of deleted mtDNA in blood and muscle
samples” (1-30)
Family number Generation Age (years)® Lab number Tissue
Muscle Blood
01 GGC 24 1/85 44.6 39.3
01 GD 49 2/86 46.3 35.6
01 D 69 3/87 70.8 45.7
01 GGM 91 4 - 53.2
03 GGC 4 5 16.7
03 GGC 13 6 - 16.9
03 GD 30 7/88 66.3 47.0
03 D 49 8/89 42.3 38.6
03 GGM 69 9 - 49.9
04 GGC 2 10 32.2
04 GD 42 11/90 64.0 30.3
04 D 69 12/91 25.0 48.3
04 GGM 91 13/92 30.0 28.4
05 GGC 5 14 16.5
05 GD 24 15/93 51.1 28.2
05 D 52 16/94 32.1 12.5
05 GGM 74 17/95 21.4 21.2
06 GGC 5 18 33.7
06 GD 35 19/96 34.0 29.2
06 D 63 20/97 29.1 14.0
06 GGM 83 21/98 77.7 60.4
07 GGC 8 months 22 34.8
07 GD 19 23/99 41.1 34.2
07 GD 19 24/100 35.6 24.1
07 D 42 25/101 11.7 52.9
07 GGM 73 26/102 22.0 66.3
08 GGC 9 27 11.0
08 GD 36 28 - 78.5
08 D 58 29/103 57.9 44.0
08 GGM 80 30 - 64.3
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Table 7. (Continued) The proportion of deleted mtDNA in muscle and blood samples” (31-57)
Family number Generation Age (years)® Lab number Tissue
Muscle Blood
09 GGC 3 31 - 28.7
09 GD 38 32/104 51.3 27.5
09 D 63 33/105 28.8 38.9
09 GGM 99 34/106 20.5 62.4
10 GD 18 35 28.0
10 D 38 36 - 38.4
10 GGM 69 37 - 49.9
11 GGC 3 38 41.0
11 GD 26 39/107 65.3 36.6
11 D 47 40/108 33.4 50.0
11 GGM 76 41/109 15.8 43.2
12 GD 24 42/110 36.8 23.4
12 D 49 43 42.3 38.6
12 GGM 69 44 - 49.9
13 GGC 10 months 45 24.0
13 GD 28 46 - 22.0
13 GD 31 47 - 34.1
13 D 48 48 - 55.5





15 GGC 15 54 47.0
15 GD 33 55 - 35.0
15 D 59 56/111 14.4 45.8
15 GGM 80 57 - 64.3
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Table 7. (Continued) The proportion of deleted mtDNA in muscle and blood samples” (58-84)
Family number Generation Age (years)® Lab number Tissue
Muscle Blood
16 GD 30 58 28.6
16 D 53 59 - 48.8
16 GGM 78 60 - 39.1
17 GGC 5 61 42.8
17 GD 24 62 - 35.2
17 D 49 63 - 38.5
17 GGM 69 64 - 49.9
18 GGC 4 65 18.8
18 GD 26 66 - 26.9
18 D 49 67 - 38.5
18 GGM 69 68 - 49.9
19 GD 20 69 19.7
19 D 36 70 - 42.4
19 GGM 69 71 - 42.6
20 GGC 10 months 72 22.0
20 GD 20 73 - 44.3
20 D 44 74 - 35.1
20 GGM 62 75 - 37.6
21 GGC 29 76 35.9
21 GD 49 77 - 39.6
21 D 68 78 - 46.8
22 GGC 23 79 22.6
22 GD 58 80 - 31.9
22 D 82 81 - 43.2
23 GGC 8 82 23.9
23 GD 46 83 - 24.9
23 D 66 84 - 58.0
”GGM = Great grandmother, D = Daughter, GD = Granddaughter, GGC = Great grandchild 
"tJnless indicated explicitly otherwise
Proportion o f Deletions in Blood versus Muscle Samples
The McNemar Chi-Square test consisted of two variables (blood and muscle) and four possible 
outcomes that is, the number of individuals with proportion of deleted mtDNA < or > the median 
proportion within each age cohorts of the two variables.
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<Median Cell “a” = 7 Cell “b” = 6
>Median Cell “c” = 5 Cell“d” = 9
N = 27 (“z”critical = L96) 
p  =  0.05
McNemar 'Y ' test = 0 J kappa statistic = 0.18
This Chi-Square was used to test the null hypothesis that the proportions of 4977-bp deletion in a 
sample of blood will be equal to proportions 4977-bp deletion in a sample of muscle. The 
McNemar Chi-Square observed (x̂ <*s) was 0.3 and the chi-square critical aid was 1.96 or P<  
0.05. Because the x̂ obs was less than the ait the null hypothesis was accepted (Table 8).
After computing the McNemar to determine the paired comparison differences in the 
proportion of 4977-bp deletion in blood versus muscle we evaluated the measure of agreement on 
the proportion of 4977-bp deletion between blood and muscle using the Kappa Statistic. The 
kappa statistic was 0.18 and the ait was 1.96 o r f  < 0.05. Because the Kappa Statistic was less 
than the ait the agreement existing between blood and muscle for the proportions of 4977-bp 
deletion was not considered to be significant.
Proportion o f Deletions in Blood and Muscle Samples Across age Cohorts 
When using the technique described by Fleiss to compute the proportions of the 4977-bp 
deletion in blood and muscle samples across age cohorts, it was necessary to separate the 
participants into two groups. After examining a number of studies relating to the detection of the 
4977-bp deletion *5.86.87.88̂  we concluded that in a given sample of individuals’ age ranging from 0 
to KX3 years, the average proportion of 4977-bp deletion detected would be 30 % of the total
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mtDNA. Therefore we designed two categories (< 30% or ̂ 0 % ) deleted mtDNA and assigned 
each participant accordingly (Table 9 and Table 10).
The Comparison of “m” Proportions from several independent samples described by Fleiss was 
used to determine whether chronological age influenced the proportion of 4977-bp deletion from 
blood and muscle across the four age cohorts (GGM, D, GD and GGC). This statistic tested the 
second ( H o  2 )  and third ( H o  3 )  null hypotheses. The second null hypothesis stated that the 
proportion of 4977-bp deletion from a sample of blood across the four cohorts is equal. The x̂ obs 
in blood was 11.85 and the x^ ait was 7.815. Since the x̂ obs in blood was greater than the x" ait 
the null hypothesis was rejected.
Table 9. The proportion of individuals with deletions > 30% deleted mtDNA in blood 
samples of the four generations within the study 
(The Comparisons of m Proportions)*
Generation # of Participants # of Individuals with 
deletion > 30%
Proportion of Individuals 
with deletions > 30%
1-GGM 11 9 0.818
2-D 19 17 0.895
3-GD 23 12 0.522
4-GGC 18 8 0.444
Overall 71 46 2.679
"A 30% proportion of deleted mtDNA was used for statistical purposes to separate 
individuals into two categories (< 30% or ^ 0 % )
The significant x̂ obs for both blood and muscle necessitated post hoc pairwise comparison to
locate the significant difference between age cohorts. The results of the pairwise comparison for
blood are shown in Table 11.
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Table 10. Summary of significant difference between the age cohorts for the proportion of 
deleted mtDNA in blood samples'





GGM &D 0.38 3.841 Non significant (0.38 < 3.841)
GGM&GD 6.22 3.841 Significant (6.22 >3.841)*
GGM&GGC 3.94 3.841 Significant (3.94 > 3.841)*
D & G D 11.01 3.841 Significant (11.01 >3.841)*
D&GGC 8.50 3.841 Significant (8.50 > 3.841)*
GD&GGC 0.24 3.841 Non significant (0.24 < 3.841)
X*crit = 3.841 f  <0.05
*For there to be statistical significance the (x̂ obs) must be greater the (x* ait)
'GGM = Great grandmother, D = Daughter, GD = Granddaughter, GGC = Great grandchild.
The results indicated that GGM differed significantly in the proportion of 4977-bp deletion for 
blood versus GD and GGC but not when compared to their immediate daughters (D). This 
finding is illustrated with the graph of proportion of deletion in blood shown in Figure 3.
The Proportion of Deleted mtDNA In Blood 
Samples of four Age Cohorts
Figure 3.
1 (GGM) 2(D) ' 3 (GD)
Generation
4 (GGC)
The proportion of individuals with deletions > 30% deleted mtDNA in blood 
samples of the four generations within the study
The third null hypothesis stated that the proportion of 4977-bp deletion for a sample of muscle 
across three (3) cohorts of i) GGM, ii) D and iii) GD is equal. The x̂ obs in muscle was 8.81 and
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the ait was 5.991. Since the x^oIh in muscle was greater than the ait the null hypothesis was 
rejected.
Table 11. The proportion of individuals with deletions > 30% deleted mtDNA in muscle 
samples of three (3) generations within the study (The Comparisons of m 
Proportions)’
Generation # of Participants # of hidividuals with 
deletion > 30%
Proportion of Individuals 
with deletions > 30%
1-GGM 6 2 0.333
2-D 10 5 0.500
3-GD 10 10 1.000
Overall 26 17 1.833
*A 30% proportion of deleted mtDNA was used for statistical purposes to separate 
individuals into two categories (< 30% or ̂ 0 % )
Similarly, the proportion of 4977-bp deletion for blood with daughters (D), while not 
significantly different (p < 0.05) from their mothers (GGM) was significantly different, from both 
their daughters (GD) and their granddaughters (GGC). Granddaughters and GGC were not 
significantly different from each other in their proportion of 4977-bp deletion. The results of the 
pairwise comparison for blood are shown in Table 11 and for muscle, shown in Table 12.
Table 12. Summary of significant difference between the age cohorts for the proportion of 
deleted mtDNA in muscle samples'





GGM&D 0.433 3.841 Non significant (0.433 <3.841)
GGM&GD 7.48 3.841 Significant (7.48 > 3.841)*
D &G D 6.65 3.841 Significant (6.65 > 3.841)*
X^ crit — 3.841 f  <0.05
♦For there to be statistical significance the (x ^ o ts )  must be greater the ( x ^  a it)
GGM = Great grandmother, D = Daughter, GD = Granddaughter, GGC = Great grandchild.
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In muscle, only three cohorts were used for comparison of the 4977-bp deletion. The results 
illustrated in Figure 4 are consistent with the post hoc analysis in Table 12. GGM did not differ 
significantly (p < 0.05) from their daughters in the proportion of 4977-bp deletion. However, 
GGM were significantly different (p < 0.05) from their granddaughters (GD) in the proportion of 
4977-bp deletion. However, daughters (D) who did not differ significantly (p < 0.05) from their 
mothers (GGM), differed significantly (p < 0.05) from their daughters (GD).
The Proportion of Deleted mtDNA In Muscle 
Samples of Three Age Cohorts
1 (GGM) 2  (0 ) 
Generation
3  (GD)
Figure 4. The proportion of individuals with deletions > 30% deleted mtDNA in muscle 
samples of three generations within the study
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DISCUSSION
In this study we investigated 21 maternal lines, and by optimizing the PCR protocol, the use of 
longer primers, a more sensitive polymerase, and shorter PCR products, we were able to 
effectively isolate and quantify the 4977-bp deletion in both blood and muscle samples from 
participants of different age cohorts, including 8-month-old infants. The results clearly 
demonstrated that there was an age-association with the 4977-bp deletion in blood samples 
however, we did not identify any increased accumulation of the deletion in muscle tissues with 
time. We revealed some compelling and interesting results in several aspects of this study and 
the following discussion will assist in explaining; First how we were able to successfully detect 
the 4977-bp deletion in blood (a mitotic tissue) and muscle (a post mitotic tissue), second the 
influence of chronological age on the proportion of the 4977-bp deletion and finally the influence 
of other factors that may have affected the presence and/or frequency of the 4977-bp deletion. It 
is unclear why muscle revealed a decrease in the proportion of the 4977-bp deletion as age 
increases. Accordingly to the literature muscle cells revealed a high proportion of the 4977-bp 
deletion as age increases therefore, if blood and muscle samples are taken from the same 
individual, both samples are expected to present similar deletion patterns. Since this was not the 
case in our study some possible explanations might be the limitations that we encountered with 
our quantification procedure and the comparatively small sample size (n = 27) for the muscle 
samples.
Mitotic versus Post mitotic Tissue
We analyzed mtDNA from both blood and muscle samples and there was no significant 
difference (p < 0.05) found in the proportions of the 4977-bp deletion in the two samples. In 
addition we evaluated the measure of agreement on the proportion of 4977-bp deletion in blood 
and muscle samples, and it was observed that there was no significant agreement (p< 0.05), that is 
the two samples were not exactly the same.
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Blood and the 4977-bp Deletion
In a previous study post mitotic tissues (muscle, lung and testis) and a mitotic tissue (blood) 
were analyzed and the presence of the 4977-bp deletion were demonstrated in all the post mitotic 
tissues, but were undetectable in the mitotic tissue. In addition, Meissner et al. ”  failed to 
demonstrate the accumulation of the 4977-bp deletion in mitotic tissues such as blood, platelets 
and peripheral blood mononuclear cells. More recently, several researchers were able to 
detect deletion specific fragments in blood samples. Gattermann et al. ^  detected the deletion in 
blood of individuals in the absence of any known hematological diseases. However, patients 
examined in this group had undergone cardiac surgery, and it can be assumed that marked 
pathological changes were present due to coronary heart disease which may have been 
accompanied by a rise in the 4977-bp deletion in the blood of these patients. As well, von 
Wurmb et al. “  used both intravital blood and postmortem blood to detect the 4977-bp deletion 
but it might be argued that the postmortem process may have contributed to an increased 
proportion of 4977-bp deletion. In addition, the presence of this deletion in some of the samples 
may be related to certain disease conditions as some of the donors were suffering from diseases 
capable of inducing an increased accumulation of 4977-bp deletion in blood. In our study, to 
eliminate the effects of disease or postmortem processes we utilized only intravital blood samples 
from participants free from any known disease conditions.
The fact that we were able to detect this deletion in blood samples of all the individuals (n = 71) 
was quite significant. Until recently it has been assumed that damaged mtDNA only occurs in 
post mitotic, well differentiated tissues and that blood cells, like fetal cells do not survive long 
enough to accumulate mtDNA deletions. For this reason blood samples have often been used 
as negative controls Further, it has been proposed that frequent cell division in hematopoetic 
precursors select against the survival of cells with genetically defective mitochondria. As a 
result we investigated and compared blood (a mitotic tissue) and muscle (a post mitotic tissue)
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from 27 participants to see whether mitotic tissues would yield different proportions of mtDNA 
deletion than post mitotic tissues. From our results we were able to demonstrate that blood 
samples accumulated sufHcient mtDNA deletions that were detectable using our improved PCR 
protocol. In addition, there was no significant difference between the two types of tissues.
In support of our results Liu et al. ^  was able to detect the 4977-bp deletion in other mitotic 
tissues such as skin from subjects of various ages. Previously Lee et al. argued that post 
mitotic tissues such as muscle and testis do not replicate and as a consequence present high 
deletion rates in these tissues. Also, there appears to be more deleted mtDNA in the tissues that 
turn over slowly or not at all (e.g. brain and muscle) as compared to those that turn over more 
rapidly (e.g., lung and blood cells). Significantly, this means that cells with lower mitotic 
activity bear high levels of 4977-bp deletion. However, we detected the 4977-bp deletion in 
both blood and muscle samples in the absence of any significant differences between the two 
samples and therefore concluded that blood may be used in lieu of muscle as a reliable source for 
the study of deletions in mtDNA.
Stem Cells and the 4977-bp Deletion
There has been some evidence that bone marrow stem cells (the precursor for blood cells), may 
contain low levels of mtDNA deletions which is contrary to the proposal that frequent cell 
division in hematopoetic precursors select against the survival of cells containing genetically 
defective mitochondria. These cells would not proliferate long enough and would therefore 
eliminate mutated mitochondrial genomes. ^  However, clinical and experimental evidence has 
provided for selection against proliferating cells harboring deletions of mtDNA that is, there is 
a progressive loss of deleted mtDNA during invitro cell proliferation. The presence of the 4977- 
bp deletion in blood of 8-month-old infants in our study raises the question whether mitotic 
tissues are able to accumulate detectable amounts of mtDNA deletions.
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If proliferating cells expressing the 4977-bp deletion have a growth disadvantage, how does one 
explain the presence and persistence of this common deletion in normal adult bone marrow, and 
more importantly its presence in 8-month-old infants in the present study? First, it must be 
recognized that in contrast to post mitotic tissues, mtDNA mutations in the bone marrow can only 
persist if they occur in self-renewing stem cells. “  Second, it is unlikely that mutations of 
mtDNA will affect the survival of stem cells, because such cells spend most of their time in the 
resting phase (Go) of the cell cycle. “  Only after initiation of cell division with its consequent 
increase in the cell’s energy do the cells become susceptible to mitochondrial defects. Since 
blood cells originate from the bone marrow, which is a mitotic tissue, we believe that in our study 
blood cells from the bone marrow maintained sufficient mtDNA deletions for their detection. In 
addition, it must be noted that although cells containing deleted mtDNA may grow slowly the 
deleted ones may replicate more efficiently, due to their smaller size. In addition, the cellular 
selection favoring normal mitochondrial genomes may not be a rapid process. The presence of 
the 4977-bp deletion in bone marrow stem cells may explain why the deletion persists in blood 
cells long enough for detection in all our 71 blood samples.
However, arguing against the occurrence of the 4977-bp deletion exclusively in resting cells is 
the observation that more than 99% of peripheral blood lymphocytes subsist in the Go phase “ , 
which would mean that the deletion should be easily detectable in blood. The fact that we were 
able to detect the 4977-bp deletion in all blood samples (n = 71) was a strong endorsement of the 
argument expressed by Gerdes etal. ^  In addition, it has been observed that about 40% of 
circulating lymphocytes have a life span that exceeds 6 months and a number may in fact persist 
for over 30 years. This should provide sufficient time for these cells to accumulate 
mitochondrial alterations that are detectable using sensitive PCR assay and may help to explain 
the recent detection of the 4977-bp deletion in blood by ourselves and others.
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Muscle and the 4977-bp Deletion
Researchers have demonstrated that tissues with high oxygen consumption (brain, heart, and 
skeletal muscle) have significantly higher levels of mtDNA deletions than most other tissues. ^  
Furthermore, the 4977-bp deletion has been shown to be present in well-differentiated cells with 
low mitotic rate, such as brain and muscle cells ”  In this study, the fact that we were able to 
detect the 4977-bp deletion in all muscle samples (n = 27) proved to be consistent with studies 
conducted by other researchers in identifying muscle as a reliable source for the study of 
mutations in mtDNA.
In spite of recent evidence that the 4977-bp deletion may be detected in mitotic tissues, most 
researchers have still only been able to demonstrate the presence of the 4977-bp deletion in well- 
differentiated tissues. This poses the question as to why there have only been only a few 
successful attempts to isolate and detect the 4977-bp deletion in mitotic tissues.
Improved Methodoloev
It might be argued that the failure of other groups to detect the 4977-bp deletion in blood of non­
diseased participants may be attributed to technical problems such as the method of DNA 
isolation, amplification and detection of the amplified fragment. By employing a variety of 
technical approaches, we developed for the first time a simple methodology for collecting, storing 
and isolating DNA for PCR amplification. This method involved the dry storage of DNA 
followed by a protocol for elution and quantification of the DNA. It has been firmly established 
that the most common method for demonstrating the 4977-bp deletion involves the amplification 
of deletion-specific fragments and subsequent detection of the PCR products on ethidium 
bromide stained agarose gels However, employing this methodology limits detection at 
the nanogram level. Fortunately, Bassam et al. ^  developed a technique that is more sensitive 
for the detection of nucleic acid at the picogram level, by specific reduction of silver ions.
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Further modification of the PCR technique was achieved by von Wurmb et ai. as they 
optimized the PCR protocol by the use of longer primers, and visualization of amplification 
products on silver-stained PCR gels enabling them to detect the 4977-bp deletion in a high 
percentage of blood samples from subjects representing a wide spectrum of ages. Similar to von 
Wurmb et al. we employed longer primers to enhance detection of the 4977-bp deletion. 
However, in our study we did not limit our changes to the use of longer primers as we made 
additional modifications to the PCR protocol.
Recent Modification to the PCR Protocol
With our methodological improvements (using longer primers, a more sensitive polymerase, and 
also shorter amplification fragments), to the PCR protocol we were able to detect the 4977-bp 
deletion successfully in blood and muscle samples at very low template concentrations using 
conventional ethidium bromide staining. More specifically, we employed 22-bp primers, small 
deletion-specific fragments (127-bp and 177-bp) along with an extremely sensitive polymerase 
(Deep-Vent [exo-] DNA Polymerase, New England BioLabs Inc.), which produced a higher 
amplification efficiency and greater yield. According to Hilali Deep-Vent [exo-] DNA 
Polymerase, when compared with other polymerases such as Taq polymerase is the most sensitive 
polymerase in detecting template concentrations as low as 10 fg. Coupled with that, we 
employed a very sensitive quantification system (Eastman Kodak) that detected proportions of 
deletion as low as 11% of total mtDNA (Table 7). The detection of the deletion in blood samples 
from asymptomatic individuals was very important as it provides a less invasive technique to 
allow researchers to gain further insights into mutations in the mitochondrial genome.
Chronological Age and the 4977-bp Deletion
In this study with the use of a maternal line model, we investigated the effect of chronological age 
on the proportion of the 4977-bp deletion in all participants. According, to the Error
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Accumulation Hypothesis the accumulation of mtDNA deletions will increase over time. In 
support of this hypothesis revealed that the proportion of mtDNA with deletions increased 
exponentially with age. Furthermore, with increasing age there was the appearance of multiple 
deletions; the number of deletions in those over 70 was significantly higher (p < 0.05) than those 
under age 40 ‘*®. There still persists the controversy that aging is the cause of the 4977-bp 
deletion. However, some of these studies were limited by sample size, research design and 
methodology. Several recent studies have presented hypoxemia as a possible alternative to 
aging as the causative factor resulting in the 4977-bp deletion. In our study we confirmed that 
aging was not the sole factor causing the 4977-bp deletion since the proportion of mtDNA 
deletion in the blood of daughters (X age = 52.2) was not significantly (p < 0.05) lower than that 
of great grandmothers (X age = 79.6). This result is contrary to the work of several researchers 
47.48.49 gg [hgy investigated the age-association with the common deletion and observed that the 
4977-bp deletion increased with age. However, an association of the 4977-bp deletion 
exclusively with aging is not consistent with our finding as we detected the 4977-bp deletion in 
asymptomatic infants as young as 8-months-old and as well, there was no significant difference 
(p < 0.05) in the proportion of deletion between the infants (GGC) and their mothers (GD).
In support of our findings, Pallotti et al. ^  argued against the 4977-bp deletion as an aging 
phenomenon as he observed that point mutations in the mtDNA did not accumulate significantly 
(p < 0.05) with age. Furthermore it has been suggested that mtDNA deletion detected in 
“normal” individuals may be inherited or generated pre- or post-partum. ^  Few researchers have 
been able to demonstrate the 4977-bp deletion in very young children. It has been suggested that 
mtDNA deletions in normal adults as well as children may be inherited. This conclusion was 
based on detection of the 4977-bp deletion in individuals as young as 3 years ” , however, there 
were only two 3-year-olds in this study and one sample was from an autopsy case and the other 
was affected by a mitochondrial disorder. As mentioned previously it has been suggested that
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samples firom autopsy cases and those affected by an underlying disease may elevate the 
proportion of mtDNA deletions. This may help to explain why Tengan et al. ”  were able to 
detect this deletion in 3-year-olds. However, supporting the woric of Tengan et al. ” , Chen et al. 
”  were able to detect the 4977-bp deletion in oocytes. Apparently, the genetic bottleneck that has 
been proposed to filter defective mtDNA molecules seems to precede the mature oocyte stage ” , 
indicating that if a deletion is present in the oocyte, it will be transmitted to the embryo. ”  
Consequently, many of these mtDNA deletions would be generated during early life, but may 
only be detected with accumulation over several years. ”  This provides a possible explanation 
why we were able to detect the 4977-bp deletion in infants as young as 8-months-old using our 
more sensitive detection methodology than previously employed.
In our study it was observed that the proportion of deletion in blood was statistically significant 
(p< 0.05) across four (4) age cohorts studied and the proportion increased as age increased. 
Likewise, the proportion of deletion in muscle was statistically significant (p< 0.05) across the 
three (3) age cohorts studied, however, muscle samples did not show an increase in the proportion 
of 4977-bp deletion with an increase in age possibly due to methodological limitations and or the 
small sample size of the blood samples. Furthermore, pairwise comparison was used to locate the 
significant difference between age cohorts for both muscle and blood and the results 
demonstrated that only certain age cohorts contributed to the significant difference (p< 0.05) 
[tables 10 & 12]. It was observed that GGM were significantly higher (p < 0.05) in the 
proportion of 4977-bp deletion for blood versus GD and GGC. Similarly, daughters (D) were 
significantly higher (p < 0.05) than their daughters (GD) and their granddaughters (GGC). Also 
in muscle, GGM were significantly lower (p < 0.05) than their granddaughters (GD) in the 
proportion of 4977-bp deletion. Likewise daughters (D) were significantly lower (p < 0.05) than 
their daughters (GD).
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As a consequence of the variability of the age-associated mtDNA deletions, Wei ”  established 
four criteria for associating mtDNA with aging. First, the deletion should only be present in 
appreciable amounts in the mtDNA of elderly human subjects; second, the incidence and 
abundance of the deletion should be increased with age of the subject; third, the deletion should 
be detectable in asymptomatic elderly subjects. Finally, the scope of the deletion must be 
distinctively revealed by the primer-shift PCR method.
Our results differed significantly from the “Wei criteria” in establishing the 4977-bp deletion as 
truly an aging deletion. We observed mtDNA deletions in substantial amounts in children as well 
as in elderly participants. In our research we report the existence of the deletion in all infants (n = 
18) in the absence of any known mitochondrial disorder. The results indicated that GGM differed 
significantly in the proportion of 4977-bp deletion for blood versus GD and GGC but not when 
compared to their immediate daughters (D). Similarly, the proportion of 4977-bp deletion for 
daughters (D), while not significant from their mothers (GGM) was significantly different from 
their daughters (GD) and their granddaughters (GGC). Granddaughters and GGC were not 
significantly different in their proportion of 4977-bp deletion.
In muscle the GGM did not differ significantly from their daughters in the proportion of 4977-bp 
deletion. However, GGM were significantly different firom their granddaughters (GD) in the 
proportion of 4977-bp deletion. Likewise daughters who again did not differ significantly from 
their mothers (GGM) in the proportion of 4977-bp deletion differed significantly from their own 
daughters (GD). Therefore, our results do not support the 4977-bp as solely an age-associated 
event due to the fact that there was the presence of the deletion in children as young as 8-months 
of age. Therefore, failure of our results to comply with two of the “Wei criteria” raises the 
possibility that other factors may contribute to the presence of the 4977-bp deletion.
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Alternative Factors Affecting the 4977-bp Deletion
Our results do not support the 4977-bp deletion as primarily an aging deletion and therefore may 
not serve as a sensitive biomarker of the aging process. This deletion seems to be quite 
ubiquitous and it could be argued that maternal inheritance, certain mitochondrial diseases or 
environmental factors such as tobacco smoke may have contributed to the 4977-bp deletion.
Maternal Une Transmission o f the 4977-bp Deletion
Importantly, it has been well documented that the identical mtDNA is transmitted from mother to 
child at the point of conception and is of high fidelity. In support of this, Chen et al. ”  argued 
that age related deletions are not transmitted to the embryo because there is a genetic 
“bottleneck”, which would filter the mtDNA molecule. Our research design was based on the 
premise that a homogeneous set of mtDNA would be transmitted from mother to child and any 
differences seen in the mtDNA profile of offspring within a generation would be as a result of age 
or environmental factors. However, arguing against the genetic “bottleneck” were the recent 
findings of, female mice harboring heteroplasmic mtDNA point mutations that transmitted a 
variable amount of hetroplasmic mtDNA to their offspring. In addition, it has recently been 
reported that women harboring mtDNA deletions appear to transmit them to their offspring.
Further evidence to support the maternal passage of information pertinent to mtDNA deletions is 
the presence of the 4977-bp deletion in very young children with mitochondrial disorders. For 
example, the expression of the 4977-bp deletion was evident in a family in which the mother had 
progressive external ophtalmoplegia (PEO), and her 4-year-old son had Pearson-marrow pancreas 
syndrome. Additional proof for maternal transmission of mtDNA deletions was the recent 
report by Bai and Seidman who identified the 4977-bp deletion in lymphocytes of a pedigree 
of a family suffering from bilateral sensor neural hearing loss (SNHL); interestingly this deletion 
was present in a 6-month-old with SNHL. In the present study, we identified the 4977-bp
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deletion in asymptomatic 8-month-old infants. It has been suggested that the heteroplasmic 
presence of the 4977-bp deletion in mother and child may be due to stochastic segregation of the 
heteroplasmic mtDNA in the oocytes, coupled with a “bottleneck” at which only few of the 
thousands of mtDNA in every oocyte are selected to populate the organism. Significantly, 
individuals bom with mutant mtDNA would start with a lower OXPHOS level compared to those 
with a normal genotype and with increasing age as their residual OXPHOS capacity declines it 
may exceed organ specific energetic thresholds resulting in the earlier onset of disease.
Disease and the 4977-bp Deletion
Although the concept of mitochondrial disease(s) was first introduced " a s  early as 1962, it was 
only in 1988 that two pioneering reports showed an association of mtDNA mutations with certain 
disease conditions. In recent years a variety of chronic degenerative diseases have been 
demonstrated to result from mutations in mtDNA. "  Therefore, it was absolutely necessary to 
ensure that all our participants were free from any known disease condition by completing an 
extensive health survey. The results revealed that all the participants appeared to be free of any 
known mitochondrial disease.
Smoking and the 4977-bp Deletion
Exogenous factors such as tobacco smoke have been demonstrated to influence the level of 
deleted mtDNA.‘“ ’‘°̂  Lui et al. demonstrated that the 4977-bp deletion occurred more 
frequently in the hair follicles of smokers than those of non-smokers. As well, a more recent 
study by Lee et al. revealed that the frequency of deletions in human lung tissue was both age 
and smoke dependent. Several studies have shown that oxygen free radicals can also be produced 
exogenously as a component of tobacco smoke. Kiyosawa et al. indicated that cigarette 
smoking induces oxidative DNA damage in peripheral blood cells in a relatively short period of 
time. In our study, the health survey revealed that either indirect or direct tobacco smoke affected
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43 participants. As a result, twelve (12) third and fourth generations and 17 families overall were 
affected by either indirect or direct tobacco smoke. The cause of mtDNA deletion by tobacco 
smoke has been attributed to the elevated levels of oxygen free radicals. Therefore, it is 
possible that the presence of the 4977-bp deletion in very young children (GGC) in our study may 
in fact be due to the substantial number of smokers associated with the maternal lines and the 
transmission of the 4977-bp deletion from mother to child.
In summary, we have developed a methodology to successfully collect, store and isolate mtDNA 
that allowed for the quantification and detection of the 4977-bp mtDNA deletion in both blood 
and muscle samples. Importantly, there were no significant differences, in the frequency of 4977- 
bp deletion, between the two samples. This is significant in that it will allow researchers to study 
aging, mitochondrial disorders and mutations in a sample of blood. In addition, we were the first 
to demonstrate substantial amounts of this deletion in asymptomatic infants as young as 8-month 
old. Significantly, individuals bom with mutant mtDNA would start with a lower OXPHOS level 
compared to those with a normal genotype and with increasing age as their residual OXPHOS 
capacity declines it may exceed organ specific energetic thresholds resulting in the earlier onset 
of disease. The overall observation of the common deletion in all four generations provides 
important support for maternal passage for not only point mutations but also large-scale deletions. 
Lastly, with our modified methodology (the use of a maternal line and improved PCR conditions) 
we have provided important information concerning a better understanding of the nature of the 
4977-bp in the human mitochondrial genome.
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GGM=Great Grandmother, D=Daughter, GD= Granddaughter, GGC=Great grandchild
• Mother passes identical mtDNA to child
• Differences seen in mtDNA deletions within generations would be because of age or 
environmental factors
Figure A-1. The maternal transmission of mtDNA across four generations
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Figure A-2. A schematic representation of the sample and generation outline
6 6
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.









100 pi TE buffer (24 hrs)
PCR
Dénaturation, 
Extension, Annealing (DNA template, master mix, temperature)
O  Amplified PCR products 
Figure A 3. An outline of the collection, storage and PCR amplification of mtDNA
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Figure A-4. Schematic diagram of formation of the 4977-bp deletion and the fragments used 
to represent total mtDNA and deleted mtDNA. Also shown are the primers and 
their region of amplification
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Negative control — y  »
127-bp------------- X
177-bp--------
+ PAGE (Polyacrylamide gel) -
Visualization & Quantification
(based on size & light intensity)
ED AS
(Electrophoresis Documentation and Analysis 
System)
Calculation
(Proportion deleted mtDNA= 
deleted mtDNA/total mtDNA) RESULTS 
(total & deleted mtDNA
Figure A-5. A representation of the separation and quantification of
mtDNA (total and deleted).
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APPENDIX B-1 








• Label FTA card
o Name, age and date of collection (represented by a code) 
o E.g. first initial, last initial and a #
• Loading lancet pen
o Remove tip of the pen 
o Twist-off the end of a lancet
o Insert the plastic end in the lancet pen leaving the needle exposed 
o Replace the tip of the pen
• Wash hands with soap and water
• Massage a selected finger (index) optional
o Gently stroking towards the tip
• Clean finger
o Using alcohol swab
• Firing lancet pen
o Pull-back the black end of the pen (listen for the click) 
o Position the tip of the pen on the tip of the finger 
o Press the black button
• Blood collection
o Position the finger over the FTA card & gently stroke 
o As the blood settles on the finger, apply to FTA card
• Clean-up
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o Use alcohol swab to apply pressure to the finger while removing excess blood 
o Apply adhesive bandage to finger
• Lancet disposal
o Remove tip of pen
o While holding black sides of the pen, pull-back the top end of the pen (lancet 
falls out)
• Ensure that all materials containing blood are properly cleaned and disposed of.
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APPENDIX B-2
MUSCLE SAMPLING GUIDELINES AND PROCEDURES
Materials needed
• Biopsy needles (sterilized)
• 3 cc syringes
• 22 gauge needles







• Label 2 pi tubes
o Name, age and date of collection (represented by a code) 
o E.g. first initial, last initial and a #
Sterilize skin of the front of the quadriceps muscle with alcohol or bentadine solution 
Anaesthetize skin and subcutaneous tissue with 2% xylocaine (avoiding contact with 
muscle)
Incise skin and deep fascia with scalpel blade 
Insert the outer cannula of the needle in the muscle 
Insert the obturator in the cannula 
Insert the trocar in the cannula 
Press muscle bulk into needle side-window
Cut off sample by gently rotating the trocar within the obturator and a hook (small 
opening) on the trocar will take the actual biopsy
Remove needle and use trocar to evacuate specimen from within the obturator 
Close wound and seal skin with elastoplast 
Place specimen into a labeled tube and store at -80°C.
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• At the time of homogenization remove all fat and connective tissue from the samples and 
then record the weight
• To remove blood, wash the muscle samples several times in Tris buffer
• Following the wash, chop the samples with a scalpel and bring up to 20 volumes with respect
to their original weight
• Homogenize each sample on ice using a disposable hand held homogenizer (1.5 ml 
Disposable Pellet Pestle), [Kimble/Kontes, Vineland, New Jersey, USA]
• Emulsify the muscle homogenate in a NaCl solution (6CX) mM NaCl, 15mM Tris, pH 7.5) and 
apply the total volume to each circle on a labeled FTA Card
• Ensure that all materials containing muscle and blood are properly cleaned and disposed of.
• Precautions were taken when handling all body specimens (Appendix B-8).
*The muscle biopsy technique was reintroduced by Bergstrom.
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APPENDIX B-3 
STORAGE OF SAMPLE
Description of FTA Card
FTA Cards are designed for the convenient collection, storage, and subsequent purification of 
blood samples for DNA analysis, data banking, and genomics. In this research we have also used 
the FTA Cards to collect and store muscle samples homogenized in a buffer solution. The 
specimen area is constructed from FTA paper, which is impregnated with a proprietary 
formulation. The card is constructed of materials that will not affect the DNA analysis of 
samples. A cover sheet protects the samples and allows the card to stand on its own while drying.
Application of sample
Spot sample directly on the FTA Card. Allow drying 1 hour to overnight before processing 
further
Caution
Universal Precautions should be used when handling any potentially infectious human-source 
blood products
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APPENDIX B-4
DNA PURIFICATION
Extraction o f DNA for PCR Amplification (Life Technologies)
Procedure
• Using a clean 1 to 3 mm punch, remove 2-3 punches from the middle of the FTA Card 
and place them into an amplification tube with a minimum capacity is 3(X) pi
• Add 200 pJ of FTA Purification Reagent to each tube
• Cap each tube and vortex 1-2 seconds at low speed
• Allow the tubes to sit for S min at room temperature with a second brief vortex halfway 
through the incubation
• After the 5-min incubation, vortex for a third time and then carefully remove as much of 
the reagent as possible
•  Repeat steps 2 through 4 an additional two times for a total of three washes with the FTA 
Purification reagent
• After FTA Purification Reagent has been removed for the third time, add 200 pJ of TE 
(10 mM Tris-HCl, pH 8.0,0.1 mM EDTA)
• Cap each tube and vortex 1-2 seconds at low speed
• Allow the tubes to sit for 5 min at room temperature with a brief vortex half way through 
the incubation
• Pour off the TE and replace with an additional 200 pi of TE
• Cap each tube and vortex 1-2 seconds at low speed
• Allow the tubes to sit for 5 min at room temperature with a brief vortex half way through 
the incubation
• Pour off the TE and allow the FTA paper punch to completely air dry
o This will require approximately 1 hour at room temperature 
o Alternatively, placing the tube with the punch at 60°C for 30 min can accelerate 
the drying
• After processing, the immobilized DNA is fixed and stored on the FTA Card. Total 
DNA can now be eluted from the FTA Card™ (following some modifications to the 
manufacturer's instructions) by adding lOOiil of TE to the tubes containing 2 to 3 purified 
paper punches and the samples incubated at 4°C for 24hrs.
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• The concentration of total DNA in each sample can be determined by spectrophotometry 
(GeneQuant IIRNA/DNA Calculator, Pharmacia Biotech [Biochrom] Ltd., Cambridge, 
England) and then adjusted to 1 ng/pJ
• The eluted DNA is now ready for amplification
o It is recommended that 25^1 reaction volumes be used
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• Purified template DNA











• Combine 5 pi of purified template DNA, or control at a concentration of Ing/pl and 20 pi of 
master mix (PCR reagents)
• Add each sample to the appropriately labeled PCR micro plates
• The appropriate volumes and concentrations of each component of the master mix is prepared 
for a 25 pi reaction volume containing, 0.5 pi of one pair of primers (T1T2 or D1D2J [20 pM] 
and 0.25 pi of each deoxyribonucleoside triphosphate (dNTP) [0.25 pM each], 0.5 pi of 
MgS0 4  [IX], 2.5 pi thermopol reaction buffer [IX], 0.25 pi Deep-Vent (exo-) DNA 
Polymerase [0.5 units] also, 0.5 pi of Bovine Serum Albumin (BSA) [IX] (See table 3)
• Amplify samples in a PTC-225 DNA Engine Tetrad Thermocycler (MJ Research, Inc., 
Waltham, Massachusetts). The first cycle consists of a hot start at 95°C for 5 min followed 
by 30 cycles consisting of a dénaturation step at 94°C for 30s, annealing at 60°C for Imin, 
and primer extension at 72°C for 30 sec, with a final extension for 10 rain at 72°C
• Add a drop of mineral oil to prevent precipitation
• Cover the plate quickly and place in the thermocycler which provides the appropriate 
temperature and time for DNA amplification to take place
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• Arrange an electrophoretic chamber using 6% polyacrylamide gel and IX TBE buffer
o Peel the tape off the bottom of the cassette
o Gently pull the comb out of the cassette. Put the comb aside so it can be used to 
separate the cassette plates at the end of the run 
o Mount the cassette(s) into the electrophoresis apparatus so the printed side faces 
the outer (anode) buffer chamber. If running only one gel, mount an appropriate 
buffer dam
o Fill the buffer chambers with appropriate amounts of running buffer 
o Use a pipette to wash the sample wells with IX running buffer, displacing any air 
bubbles in the wells
• Combine 4pl of 6X running buffer and 4pJ of each sample (total or deleted)
• Combine 4pl of 6X running buffer and 4pl of each control
• For each participant, load 4pl of each mixture (alternating total and deleted samples) to 
separate lanes on the gel (use printed lane markings as guides)
• Load 4p,l of the size/reference standard (pBR322 DNA- Msp 1 Digest) and 4pl of the 
appropriate control in separate lanes
• Attach the electrophoresis apparatus to the power supply and run the gel(s) at a constant 
voltage of 130 V, 5(X)A for 45 min or until the dye front is near the bottom of the gel(s).
• When the run is complete, shut off power and remove gel(s).
• Place the cassette(s) on a flat surface with the notched (well-side) facing up. Starting near the
top, work your way around the cassette using the end of the comb to separate the two plates. 
Carefully remove the short plate. The gel will adhere to either the short or long plate.
• Hold the plate with the gel over an open container. If the gel is adhered to the larger plate 
carefully insert a flat edged device (comb) through the plate's slot and gently push out the 
bottom of the gel; allow the gel to peel away and gently drop into the container. If the gel is 
adhered to the smaller plate carefully use the comb or a spatula to loosen one lower comer of 
the gel; allow the gel to peel away and gently drop into the container
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APPENDIX B-7 
PRODUCT VISUALIZATION AND ANALYSIS
Procedure
• Stain gel for 15-20 min in an ethidium bromide solution.
• Visualize PCR products using a transilluminator where the stain that is bound to DNA will 
fluoresce
e Quantify DNA bands using the Kodak Electrophoresis Documentation and Analysis System 
[EDAS]. The system captures electrophoretic images and allows you to quantify DNA bands 
based on the intensity information for each band
• ED AS software is able to determine the mass in nanograms (ng) of total mtDNA and deleted 
mtDNA in each sample
• Determine the proportion of deletion in each sample by calculating the ration of total to 
deleted mtDNA
8 0
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APPENDIX B-8
PRECAUTIONS
Since these procedures involve the handling of fresh, human tissues, precautions must be taken to 
minimize the risk of infection with HIV, hepatitis B and other agents. Therefore: -
• Wear protective clothing
• Cover working area with disposable material
• Wash hands properly
• Wipe with a disinfectant such as hypochlorite after use
• Sterilize instruments after use
• Dispose of all human remain safely
• Label specimens accurately and store safely
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APPENDIX B-9 
PCR QUALITY CONTROL 
To address the issue of PCR saturation
• Tubes labeled (1-5) with the same samples were ran at 26,28,30,32 & 34 cycles
• 95°C 5 min- Hot start, 94°C 30s- Dénaturation, 60°C 1 min- Annealing, 72°C 30s- Extension, 
72°C 10 min- Rnal extension.
• After quantification, the highest cycle that showed incremental changes in DNA band 
concentration levels was used as the amount of cycles in the study. This addressed the 





Figure. B-1. Graph showing PCR saturation and how the number of cycles used in the study 
was derived. This graph shows that as the number of PCR cycles (x-axis) 
increases the % saturation (y-axis) of the PCR increased. The reaction is within 
its linear phase at approximately 15-35 cycles. However after about 40 cycles 
the graph plateaus and the PCR saturation point is reached. For the purpose of 
this study 30 cycles was used, that is within the linear phase of the reaction and 
not at the saturation point. This is the optimal number of cycles that has 
demonstrated the best PCR product yield and choosing the reaction cycles before 
saturation will ensure that quantities of different PCR products can be best 
determined before the end of the reaction.
To address the issue of primer specificitv 
• A primer switch was done
o The pair of primers (D1D2) that is designed for deleted mtDNA (127-bp) was 
used in an attempt to amplify total mtDNA (I77-bp)
8 2
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o There was no amplification. This addressed the concern of primer specificity 
(Figure B-2)
Figure B-2. Electrophoretogram of the PCR products amplified from mtDNA with the 4977- 
bp deletion. Lane 1 indicates the 177-bp (total mtDNA) amplified by primer 
pairs T1T2. Lane 2 is deleted mtDNA amplified by primer pairs T 1T2. Lane 3 is 
total mtDNA amplified by primer pairs D1D2. Lane 4 indicates the 127-bp 
(deleted mtDNA) amplified by primer pairs D, D2 . Lane S indicates the positive 
control of blood from an 85-year-old male. A multiplex PCR (177-bp [total 
mtDNA] and the 127-bp [deleted mtDNA] amplified by the two primer pairs 
T1T2& D1D2. Lane 6 indicates the negative control of ddH20 and PCR master 
mix. Lane 7 indicates the size/reference standards (pBR322 DNA- Msp I 
Digest). This proves that the primers were specific for the desired amplification 
fragments.
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To address the issue of contamination and relationship within generations
• Reagents and template contamination
o Negative controls were processed with each PCR
o Each PCR reagent was used to replace template DNA as negative controls
o Blank FTA Card pimches were simultaneously processed along side FTA
punches with sample to look for contamination of FTA Cards
o Selected fragments of the 12s region (highly conserved region of mtDNA) and
the Hypervariable Region 2, (HV2) of the template mtDNA were sequenced to
confirm the presence of single template DNA and to establish a maternal line
relationship.
o The results suggested that each sample contained only single template DNA 
indicating that there was no contamination and the 12s and HV2 regions of the 
mtDNA of all the members in each maternal line were similar suggesting that 
members’ within reach maternal lines were related.
To address the issue of reoroducibilitv
The entire methodology was repeated several times under the same conditions and the results 
were similar.
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APPENDIX C-I 
LETTER OF INFORMED CONSENT 
For participants in the following research study;
The Effects o f Chronoloeical on Mitochondrial DNA (mtDNA) Deletion in Muscle and Blood of 
Older Adults ( Using mtDNA Deletion as a Measure o f Aging).
Principal Investigator: Roy Wittock B.Sc. (Hon)
Supervisor: R. Thayer Ph.D.
Lakehead University 
Thunder Bay, Ontario P7B 5E1 
(807) 346-7815
I _________________________ , consent to participate in a study which will require completing
the National Public Health Survey which will provide the researchers with information 
concerning both my health and smoking status. In addition, I agree to provide 1 ml (one drop) of 
blood and 5-25 mg of muscle tissue (one grain of rice) in order to determine the Effects o f 
Chronological Age on Mitochondrial DNA (mtDNA) Deletion on the Aging Process. I 
understand that the blood sample and the muscle biopsy will be used to review the mitochondrial 
genome and to detect mtDNA deletion if present.
In order to investigate the effects of time (chronological age) on these deletions we will have to 
undertake a longitudinal study approach rather than a cross sectional study approach. There is 
sufficient evidence suggesting that there will be an increased amount of mtDNA deletion with 
chronological age. These deletions have been associated with certain aging characteristics as well 
as certain age-associated diseases.
It has been well established that the mitochondrion is inherited maternally that is, the mtDNA of 
the child is identical to the mother at the point of conception. Therefore, changes in the child’s 
mtDNA profile could be as a result of chronological age or some environmental factors such as 
tobacco smoke. Essentially children are "mitochondrically identical' to their mother. Using the 
mother/child relationship in this study will provide the attributes of a longitudinal study design.
Dr._______________________and_______________________ from the research team have
explained to me the entire laboratory procedure. A qualified experienced laboratory Phlebotomist 
will collect onto a FTA Card less than 1 )d of whole blood firom a finger prick using a lancet pen. 
For a brief period after the procedure however, there may or may not be a burning sensation 
similar to the sensation felt from a needle prick.
The muscle biopsy technique was reintroduced by Bergstrom ^  in 1962 and has been used 
extensively in the area of biochemistry since that time. An experienced medical doctor will take 
the muscle biopsy. In this procedure, using aseptic conditions, a small area of the biceps muscle 
will be injected with a local anesthetic (2-3 ml of xylocaine hydrochloride). Approximately 5 to
8 6
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25 mg of muscle tissue will be taken using a small biopsy needle and placed onto a FTA Card. 
There exists the possibility of a hypersensitivity reaction to the local anesthetic, in which slight 
discomfort could persist for 1 to 2 hours following the procedure. Furthermore, there exists the 
possibility of slight muscle soreness for a few days following the muscle biopsy procedure. In 
addition, if samples are taken in a highly innervated and vascularized area, there exist the 
possibility of nerve damage and arterial bleeding. However, the area that will be sampled in this 
study reduces the probability to almost nil. I am aware that the entire procedure will take 
approximately 5 minutes. Proper care and hygiene offered by the laboratory setting will 
eliminate any possibility of contamination or discomfort. All materials used in the collection of 
the blood and muscle (including the actual muscle biopsy) will be disposed as follows;
All materials will be placed in a biohazards waste collection unit
Collection units will be placed in cardboard boxes
Cardboard boxes are to be wrapped in plastic and sealed with tape
• Boxes will then be collected and disposed of by BFI Medical Waste Systems
My participation is voluntary and I have the right to withdraw from the study at anytime. I am 
also aware that all the risks and benefîts of engaging in this study have been outlined clearly. 
Results of the study may appear in a publication however; your identity will remain confidential 
at all times. Confidentially will be assured by the use of a numbering system for identification 
and names will not be used. After the completion of the research, the results will be stored 
securely for at least seven (7) years and a summary of the project will be made available to me 
upon request. I understand that the Research Ethics Board of Lakehead University has approved 
this research.
S ignature of Participant Date
Signature of Wimess Date
I have explained the nature of the study to the participant and believe he/she has understood it
S ignature of Researcher Date
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I am a graduate student in the School of Kinesiology at Lakehead University. I have also 
completed an Honors Bachelor of Science B.Sc. (Hon.) degree in Medical laboratory Sciences.
I am conducting a molecular study of the Effects o f Chronological Age on Mitochondrial DNA 
(mtDNA) Deletion in Muscle and Blood o f Older Adults (Using mtDNA Deletion as a Measure o f  
Aging). This study is being conducted under the direction and supervision of Dr. Robert Thayer, 
Professor in the School of Kinesiology. Upon successful completion of this research I will 
partially fulfill the requirements of the Masters of Science (MSc.) degree in Applied Sports 
Science with a specialization in Gerontology.
With the knowledge and experience I gather from this study as well as the completion of my 
degree, I will be able to contribute to the development and advancement of Medical Science. 
With a specialization in Gerontology, I will be well aided to make new discoveries or clarify 
existing ideas pertaining to the effects of Chronological Age on the aging process. Your 
participation in this study will allow me to provide a greater understanding and help to elucidate 
the molecular mechanism underlying the aging process.
There are several different theories attempting to explain the aging process. One of the more 
prominent theories is called Error Accumulation. This theory rest on the assumption that as cells 
get older they accumulate errors called mitochondrial DNA (mtDNA) deletions. In an attempt to 
elucidate the mechanism underlying the aging process, the mitochondrial genome in older cells 
are studied and compared to younger cells. The mitochondrion contains its own genetic material, 
a small, circular molecule containing I6,569-bp (base pairs). The mitochondrial genome, 
however, is extremely susceptible to DNA deletion when compared to nuclear DNA. The most 
frequent deletion is blown as “the common deletion” or 4977-bp deletion. The causative agents 
of this deletion include oxygen free radicals, a normal byproduct of ATP production. It has been 
shown in existing literature that there is a strong association between mtDNA deletion, 
chronological age and the aging process in post mitotic tissues such as muscle and brain. 
However, there are several limitations to these existing research studies for example, they have 
relied on data obtained from cross-sectional studies and not on longitudinal studies. In order to 
address these limitations, a longitudinal study model will be used. The model is designed out of 
the fact that there is maternal transmission of mtDNA. Therefore, the attributes of a longitudinal 
study design will be realized by investigating the mtDNA deletion pattern of five (5) different 
maternal lines ranging from Great grandmother (GGM) to Great grandchild (GGC) [4 
generations].
A qualified experienced laboratory Phlebotomist will collect and store, onto a FTA Card less than 
1 ml of whole blood from a finger prick using a lancet pen. For a brief period after the procedure 
however, there may or may not be a burning sensation similar to the sensation felt from a needle 
prick.
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The muscle biopsy technique was reintroduced by Bergstrom ^  in 1962 and has been used 
extensively in the area of biochemistry since that time. An experienced medical doctor will 
collect the muscle biopsy. The medical persoimel will be Rob Petrella MD, PhD., an adjunct 
professor to the School of Kinesiology and Medical Director, Center for Activity and Aging, 
University of Western Ontario. In this procedure, using aseptic conditions, a small area of the 
biceps muscle will be injected with a local anesthetic (2-3 nil of xylocaine hydrochloride). 
Approximately 5 to 25 mg of muscle tissue will be taken using a small biopsy needle then stored 
onto a FTA Card. The method of analysis will be a modified version of the polymerase chain 
reaction (PCR) techniques (a standardized laboratory technique used to identify and quantify the 
mtDNA deletions in blood and muscle samples). Electrophoresis and densitometry will be used 
for the final detection and quantification of the mtDNA deletion.
There exists the possibility of a hypersensitivity reaction to the local anesthetic, in which slight 
discomfort could persist for 1 to 2 hours following the procedure. Furthermore, there exists the 
possibility of slight muscle soreness for a few days following the muscle biopsy procedure. In 
addition, if samples are taken in a highly innervated and vascularized area, there exist the 
possibility of nerve damage and arterial bleeding. However, the area that will be sampled in this 
study reduces the probability to almost nil. The entire procedure will take approximately 5 
minutes. Proper care and hygiene offered by the laboratory setting will decrease the risk of 
contamination or discomfort. All materials used in the collection of the blood and muscle 
(including the actual muscle biopsy) will be disposed as follows;
• All materials will be placed in a biohazards waste collection unit
• Collection units will be placed in cardboard boxes
• Cardboard boxes are to be wrapped in plastic and sealed with tape
• Boxes will then be collected and disposed of by BFI Medical Waste Systems
Your participation is voluntary and you have the right to withdraw from the study at anytime. 
You will be made aware of all the risks and benefits of engaging in this study. Furthermore, all 
terminology and concepts related to the study will be explained to you. Results of the study may 
appear in a publication however, your identity will remain confidential at all times. 
Confidentiality will be assured by the use of a numbering system for identification and names 
will not be used. After the completion of the research, the results will be stored securely for at 
least seven (7) years and it will be made available to you upon request. You understand that the 
Research Ethics Board of Lakehead University has approved this research.
I thank in you in advance for your interest in this research. Should any questions or concerns 
arise, please contact myself using the information provided below.
Sincerely yours,
Roy Ralph Wittock, B.Sc. (Hon)
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e s .  What ara yM dHag?
(UARK AU. TUAT APPLY, DO NOT REAO)
O’O  IMtfolian/pNs 
” 0  OuttamaUng 
” 0  ExardM ragiMly 
LaFng «MigM or 
" O  RoduconninM e 
°* 0  Ottior dM dMngo 
0*0 
" O
“ O  OBiw«p#e«W
SECTION C:
BLOOD PRESSURE & CHOLESTEROL
C l. TlM nM lM »diiM lloiww«aboulliM rthM llli.lnyaur 
•pM on. «dMt ara Ma mmIr cauaaa ar haait dtaaaaaf
(MARK AU. THAT APPLY. 0 0  NOT READ)
OF RESPONDENT SAYS. -UFESTYLE" OR ‘VIET-. 
PROBE FOR SPECIFICS)
®’0  OcnTknow
" O  SffloMno
” 0  L ackofanrdaa
®*0 Ealing Wty toodaÆtnlaalarol
" O  Batag ovarwaigM
" O  PoordM
®^0 Eating loo much aaH (aodkan)
®*0 Siraaa
" O  Famly madtoal Mtiory 
'® 0 Hlgh blood praaaura 
" O  High blood choiaitaral 
" O  Too much alcohol 
’* 0  Othar (tpteOyl
I I I I I I 1 1 I ..1. I L. I I I I I
02. Whan did you laal haw your blaod praaaura diaekadT
'O  WltMn the iaat 6  monttis 
* 0  7 -1 2  months 
® 0 1 3 -2 4  months 
*0 Mora than 2 ysars 
* 0  Donttmow
*0 Navar <SoloC6
03 . Haw you m m  boon laid by a doolor, miraa or aWiar 
haaWh pralaaalomal dial you haw lUgh Maad praaaura?





0 4 . Ara you dabigaiiylMiig la canlral yaur Maad praaaura?
*0 Yaa *0 No > Go »  0 8
■■■■■■■■
'®0 Don’t know
Oa. W arayauaw W dbyadaclar, nufaaarolharhaallh  
prataaalaaal that yaur Maad ehalaaiaral was high?
(THIS WOULD REQUIRE A BLOOD SAMPLE)
'O  YW 
» 0  No
® 0 Don’t knew/ Can’t ramambor
joo'lo Of
07. Ara you doing anyMng la aanBM yaur 
* 0  Yaa
‘O No > Go 10 Of
oa. What ara you doing?
(MARK A U  THAT APPLY. DO NOTREAD)
'O loMng weight or maintaining weight low  
® 0 Roduca ehoiaataral ki dM 
®0 Eat iaaa latty foods 
'O  Olhar change kl dM 
® 0 Exardaa ragutoly 
*0 Control strass and fatigue 
'O  Taka praacribad madkMion 
*0 OOm (v e K y )
SECTION D: EXERCISE
01. Tha east laaiquaailana ara about aiardaa. By aiarelw  
ara inaan rlgaraua aalMllaa auah as aaroMas, Jagging, 
raaguai aparta. Mara aparta. danea claawa, ar brtak
Naur many ibiiM par araak, an awmga, da you asaraiM?
(DO NOT READ)
’O Daly
® 0 5 - e  tbiws a weak
® 0 3 -4  bmwawaak 
'O  1 -2  tknw a weak 
®0 Laaa than once a araak
•O
'O  Don’t know
J  Go to 04
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OS. WhMi y« i da M a wMiciM. hov nwcli Haw ara ywi 
aeMaNy aadaat WaaM ■ aaaaSy ba—
'O  laaa Man i f  ndnaiaa?
* 0  M an an  I f  and SO ndnaiaa? 
*0 Mara Man 30 ndnaiaa?
03. Oa yaa laal Mai yaa gal a a raac b aaarclaaaa yaa naad
* 0  A» much aa naadad 
® 0 Laaa M 
•O Don't know
I ant gaMg M laad Mur aanianei 
nauiMaa aracMMMa. Tan nw nddali ana baal
(MARK ONLY ONE)
'O  1. Yau an during Ma day and da nal araftabaul
* 0  2. Yau aland araNMabaalquNa a Ml during Ma 
day, but da nal baaa M carry ar OR Mdnga vary
3. Yau Ml ar carry IgM Made, ar you havalaeMnb
* 0  4. Yau da haaay nark ar carry «cry haary Made.
SECTION E: SMOKINO
E l. Tha nail Mar quaadana ara about amablng.
Oaioff
yau arar arnakad
O Yaa *0 No
E2. Al Ma praaam dma da yau amaka dgnraoaa?
* 0  Yaa *0 No Go 10 E f




E4. M yaur day M day acMrilMa, da yau Had raaMelMna 
pMead an aihara ar adian yau can amaka?
'O  Yaa *0 N o  ► Go to 58
Ef.
'O  Ya -► Naur aa? * 0  Laaa aadi day 
Morn anch day 
*0 TrMd to quit
® 0 No. about aamn 
*0 Don? know
Ef. Naur many al lha paapla Ndng M yaur huu aahald 




ET. Oa you mmrMal unoMnannI alMcM ham Ma alaarawa 
amaka a l admra?
'O  Yaa ®0 No
SECTION F: ALCOHOL
FI. I auaaUana abant atoahal
In Ma nail guaalMna whan am uaaMa arard drink R
• Ona baOM al baar ar glnaa al Mall
•  Ona anMd gMaa a la ln a
•  Ona abal or adiad drink aWi hard Uquar
Haaa yau aaar Mkan a drink? (baar, arina. Iguor or oMar 
aioohole bawarnga)
'O  Yaa »0 No -► Go to GT
F2. In Ma paal 12 manMa. haw you Mkan a drink? (baar. 
wkw. Iquor or oMar atoohoie bnwraga)
*0 Yaa *0 No -¥■ Go 10 or
F3. In dM paal 12 manMa, hoar aiMn an aaaraga dM yau 
drinkaleahan W a a n ...
'O  Ekaryday?
4 - f  Hmaa a taaak?
'O  2-3 Umaa a araak?
* 0  Oncaawaak?
®0 Onea ar lurfca a maoM?
*0 Laaa aIMn Man anca a manM?
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F4. o(*r « •  l u i  7  day*t MmUmo «*lli 
tun y  é U U  M  iwiiM M  M  u e h  U f ?
02.
CM not my
naw pu iruy t... 'O
Y— NodM on.
“ O ®»o“ O v«
“ O NOMONDAY?





'»0  Vo. 
’•O NO
THURSDAY?FRIDAY? "O  Y« 
» 0  NO
SECTION H: ROAD SAFETY PRACTICES
F i. I'm « tur • ■bmii Hw 
• w M ll l s a m . TNs




®’0  “ O "O »o
biTo araa lln
0 * 0  06Q  OOQ
*oe)To
(ATV) orML®'0 “O ®*o
SECTION 0 :  DRUQS
'O  Y u
01. MM to a u  you ahaat yaur 
hardniga. • O  No




M3. MITERVCWER CMRK ITEMr
If FI or F2 It "Wo” 'O“ O “O
•O« 0  “ O
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SECTION I: NUTRITION
n. TiM Mit
In dM MM 7 daya, on b M  n m y  days dM yM  haw  Nw 
lodoMi a M  part a# lagr hw alrtia tT
a)Juat «aWaa. Im  or aadilap al i







15. W a u M u u M y y o u a ra ... 
*0 Vary w anw HlitT 
'O  dawaodial  ewnwIdlilT 
*0 Oaly a HMo aaanaalgm?
SECTION J: SOCIAL RELATIONSHIPS
J1. Tba mail fan qwaaUoM ara abaat ralalleeMMpa and
a) CbaaM. wdfc ar adwr dahy prodaen  *| I
(odiar dian In your coNm  or laa)__________ I__I
n .  biyaor opinion, artial ara dw law baal waya far paapM 
M taM nalgM ?
(0 0  HOT REMO — PPOBE FOU SECOND CHOKE)
(IF ANSWER IS  "TO OET-. ASK TO EXPLAIN)
®'0 HeroMa phyaical ocHvtty/aiarciM
” 0  Eat laaa «wants and augnr
Eat tOawr caioftM
®*0 Dont aat bainaan maala (anacbal
" O  sup maala
" O  Eat laaa tood (ganaraly)
®'0 Eat mora fruits and vagatablaa
°*0 Eat foods loar ki fat
®*0 Eat a balanrarf or nutrltloua dkt
’®0 Othar fapadiy;
I I ‘ I
la. Ara you non trying M tow  nalgbiT
'O  Yaa 




'O  Joal about Ngbl?
J  G oto JT
In dw paal 10 days, liaia you halpad eara far a 
ar llrland n iw  noa auffaring iWHi a pbysleal or
'O  Yaa 
'O  No
® 0 Dont loton/Nol ana
A  bi dw paal M  days, bana you 
ar awnlal boadb proMaw iarnblcb  
aara tram a lalatba or trtawdT
*0 Yaa
*0 No
*0 Dont know/Not awa
SECTION K: WORKPLACE
K1. Tha naal fan guaadona ara about your ampMynwnl
WMeb of tba iodonlno bast daaerlbM your main acM ly  
during dw laal 12 mandisT Warn yau nw inly.. .
'O  WsrUng al a Job or bualnaaa?
'O  Loafelng for nark?
A aiudom?
*0 NaWradT 
* 0  Kaapbi 
•O Othar
O o lo K S
G oto  K2
^  Go to LI
K2. OM you baas a Job or bualnaaa al any ilnw during dw  
past 12 awnibsT
'O  Yas
•O No ----------► Go to LI
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PU. Hon MUT MMlH dM yau «ork M ■ Jab or bMlMM 
dBftaf Vm  laat 12 awadia? (kwkMo vaeadon. bnaaa,
sMkaa. lock-auta and malacnny/paisnitty laava)
m Waaka
M . Far adiaw da (dM) yau aartiT
'O  Sad-amployad
IM7ERMEWER- I fm o n  Man ana/ob raportad, M  
mati/ob.
I I 1 t t I I I
-L_J ' ' ' '__ ' ■ ■__ I__ ' ' ' '
L_i I I I I I ■___l_—I__ I__I——I__I__ L.
KS. *halW nd«(bwabiaaa.lmdwabyar«anleala(iaM| l hal?
I I I I I I I  I I I 1 - I t I
■ ■ ■ ■ ■ ■ ■ _________________________________ i _
L -L  ..I L 1 I I J I 1 1 .1 --- 1--- 1_
Kd. W halUnda(Borfcda<dM)yo«daT
_l 1— 1___I— I__I— I__ 1— 1----1— I--1 1. UL
K ie. DM you lapuMrfy amrfc aaanbig ar nigbl abdlaT
’O Yaa 'O No
K11. OM you ragularfy nark on dabrrday ar OundayT
Yaa "O No
K7. lnlalal.aboal ban many paapM aw* la yaar bualnaaa 
ar company al a l  Ma MeallanaT
'O  1 10 10 
'O  Baiwaan 20  and 09 
Bauaan 100 and 400  
*0 MoralMnSOO 
*0 Oontl
aumvcwKR: KB to K12 appaas m Mjboa
KO. Haaa any ai Iba (aOaadnp eauaad yau aieaaa «mny or 
Mraaa al «aifc In iba laal ala maMbaT
No NetOeon
Vea Knov
 O'O "O  “ O
M D ulIaaaranalcIaarT .... ®*0 "O  ®*0
e)N
■ban yau da HT...............  "O  “ O
. . .  ’“O "O  '*0
paapla al a u b ? ...............  "O '*0 '»0
KO. In dw laal yaar, ban many daya awra yau anay from
***0 Donlknon
K12. Da yau fcnan d dw fadanlnp praprama ara awdabW al 
yaur plaM al nark?
Ne Net






... ®'0 “O “ O
. . .  «O “O “ O
. . .  “ O “ O
SECTION L: WOMEN’S  HEALTH
Li. n m i m e w a  check  itemt
la: 'O  Famwa ■ *  Go (o L2
*0 MNt > B otoU t
L2. Tba naal quaadama ara abaui prawmh a
Man aflan da yau 
WauM yau aay . .
® 0  A lfaaalaneaa
*0 Oneaaaary 2 4
® 0  laaaaflanT
■O Naaar?
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u .  H u# you uw r h 
X*tay?
'O  Y— ---------
•O No
'O  Dont know
I  •  mmmmogwiu. Mat la, a braaat
■ Whan waa Ma laat dma?
Laaa ttian 12 mendia #0 
®0 1 to 2 yaara ago 
* 0  Mora than 2  yaara ago 
*0 Don’t know
*0 Y a a --------
• O  No
'O  Don’t toww
had a PAP aaaaar?
— Whan waa dm laat dma?
'O  Laaa man 12 monma ago 
*0 1 to 3 yaara ago 
' O  Mora man 3  yaara ago 
* 0  Don’t know
LS. Haaa you aaar glaan bdM?
’O Yaa *0 No " ' ► S o fo L d
Lt. tn what manM and yaar waa yaur laat ehdd born?
10
L7. DM you braaal laad yaar Mat ehdd?
Haw long dM you btaaaWaad 
yaur laal ehdd?
•O Yen -
No 'O  laaa man i
•O Triad/not *0 1 — 2 i
*0 3 — 41  
*0 5 - « I  
*0 6 or mora montha
Li. Iwauldibaloaabyaualaw paraonaH uaadonaaboal
ba aaaurad that anyMIng you lad ma wilt lamain
Haw, wa wouM Mw la  know yaur ago whan you lirai had 
aaiual Inlarcouraa. TMa la Impartant Inlermaden 
baeauaa K baa aoma baaring an baalM In latar yaara. 
Do you ramambor how aM yea ware?
I  Aga
" O  Navar 1
I So ro 
**0 Raluaad to anawar J
L11




^  Go toL11
L10. In tba paal 12 mendia, wIM bow many parlnaradM yau 
baea aaxaal Iniaraeuraa?
**0 Raluaad to anawar
111. I 
to
Aftor I road aaeb
ma waye 1er paapla 
gaWtog a aaxaaiy tranamMlad
lad am d you Mink H la “ Vary 
aHaedea", ar “ Not at ad
a lA ea n d a m ? ... »’0  “ O ” 0  "‘O “ O 
MA
.. “ O O'O “ O “ O '"O
, itQ >*o ’*0 ’*0 ’»0
d)Aafcdparbiar 
haaa aaauaiy
dtoaaaa?  "O  "O  "O  "O  ” 0
a ) i u  only wdb
... "O “ O ” 0  ” 0  “ O 
0 No an , at ad? “ O ”0  " O  " O  “ O
112. Wbal do you 
idy -
'O  Mgh? 
* 0  Median
Low? 
' O  Nona?
mink your ebaneaa ara of gaMng a 
dtoaaaa? WeuM you aay May
*0 Don’t know 
*0 Akaady have an STD
L13. Dim to wbal you know about aoiuaUy 
dlaaaeae, baea you ebang# 
tba paal 12 manMa?
Yaa




a) Had aaaaal Iniareoaraa 







d) AnyMIng atoa? d p o e ty l.
•o *o 
'O *o
I I I I I I I I
mavmwBk ooum
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Hw to aafc |M i a  laar paraonal qaaaiiam abaal 
labaMoar bu aaia a i ba lawartaiica to pataaaal 
and aactol piabUaii. Oiwa again. pMaaa
Naar.arannwIdMta to lUtowyanraganitoninnlbalbad  
aamual totoreouiaa. Do you lomambar haar oM you
m Ago
"O
**0 Rafuaod to anawor
^  Go to I
In g *  paal12 mendia, haaa you had aaaual
’O Yaa 
* 0  No 
® 0 HatoaadItotnawar ^
Go to AM
M3. In dm p a a ii2  mendia, eddi how many partnaredto you
**0 Haiuaad toaneoor
I atouM now Hha your opinton on aoma maya 1er paapla 
In ganaral to pioeont gatdng a aamwally danemWi ed
AHar I laad aaeh ana, toll ma H you drink II la “Vary 
aHacdw” , “Somomhai aflacdw", ar “Nal al aH 
aHaedea ” tor oraaandnn eai nad* hananriltod dleaaear
aJAeondom?. . .  ®'0 “ O “ O “ O “ O
b)A
dtophragm? . .  “ O ”0  “ O " O  '"O
e) t pamrid dal 
ladyortaamT. ”0  "O "O ’*0 '»0
diAak H paitnor 
haaaaaxually
OT  "O  '^O " O  '*0  ” 0
aldaaanly  eddi
... *'0 **0 “ O “ O “O 
Q N o a a a a la lir  “ O ” 0  » 0  « 0
do you drink your ehnneon are e i  gadhig a  





* 0  Oonlknow 
*0 Akaady haeo an STD
Dna to ohai yau 
dtoeemee lu 
dm paal 12
' O  Yaa
• O  No — Go to NT
Yea No
a) Had aamual liriamauraa
ortdi mriy ona portnorT................. . .  'O * o
M Deadeandametorprotocdon? . . . . .  » o ‘ O
eldaan mare earalul In 
aatoodng aamual parlnara?......... . .  » o • o
d) Anydilag alaoT topockyj............... 'O  
1 1 1 1
• o
N1.
SECTION N: OBUTAL HEALTH 
N ail I mauM dko to aak you am
Do yau haeo ana ar mera al your nabiral toadiT
<0 Yaa
* 0  No ■■ »  Go to «5
N2. Haeo you aaan a dandel In dm paal 12 mondia?
* 0  Yaa 
* 0  No
® 0 Dont know
j  Go to N4
(DO NOT READ)
’O Twtoa or more a dey/altor 
*0 Once a day
® 0  A tow Hmaa a waak 
* 0  O ncaawaak
*0 A tow Hmaa a mondi 
*0 Onea a monUi
' O  Rarely/Navar 
*0 Dont know
I yourtoadi?
N3. During Hila dmo, dM yau eaa a dandai to r .. .
Yaa No
a) A dantol ehaekup or ctoanlngT — O’ O 0 * 0
b| A lUdng or ombaeden?
(non emergency)................................. 0 * 0 0 4 0
e) Any partodarrial Voolmonit 
(gum koaiinonO................................... 0 * 0 0 * 0
dIOrlhodonde boalmoni?
(bracoa)................................................ OTQ “ O
a) Crown ar brMga m ark?.................... " O lOQ
1) A dantol amarganey?........................ " O .2 0
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SECTION P: 
GOVERNMENT ACTION 
ON HEALTH PROMOTION ISSUES
O Y—
• M «• hMMi IoMm-Par Mdi r«
your apM wi ■taut hMt hapartm l f w  M  R Is for
'O  Don't know
S K T IO N O :
HOME AND ENVIRONMENTAL ISSUES 0 (1 1 0 1 0 ; « M il  boiog“ oBiroM 








OIQ “ O  “ O
"O

















I) Ouy products olodo ol 26Q OOQ OTQ
100 2 . During tho post 12 monttis, hour mueh do you RRnkRist 
owHronnionUI peHuRon Iws sftoetod your hooRh? 
Would you ooy .. .
"O
klAH»?
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SECTION Q:
HEALTH INTENTIONS — PAST AND FUTURE
0 1 . O l d i ^ d i M U MilsglDlinpwwyoMrl W h lnRiopow 12 aMMlMf
OoiaOd
'O  Y *  
*0 No
02. WiMt to * #  slmgl# — w lip o rtonl cAeng# you ho## 
modo Im dm pool 12 moiddo lo Improoo yoor kooMT
(OO MOT HEW. ÊURK OHLYOME)
°'0 taerooood oxordoo, iperti er phyoieol oeflvlty 
” 0  LootwoiaM 
”0  CkongoddMaroolinglMMo
Quit omoWmg/rodwcod tmouni tmokad 
°*0 noducod ePugftnodteofcn iMO 
" O  Drank teas dcoW  
” 0  Monogod or fodueod Wood pmoouto 
°*0 Monogod or foduood dwiooMtoi 
°*0 Manogod or rodueod sOooo 
" O  Chongod phyoleal omironmont 
" O  RocoNod modtod irootmont 
" O  Chongod ooxudbolio«lour or fodueoddsA of STOo 
" O  knprowod donli 
" O  cvmrmmeiy;






s) Support from family 
and friends...................... . ® '0 « 0 « 0
hflnoroosod knosdodgo 
of hosdh r isk s ............... . « 0 “ O « 0
e) Chongos In loglolsdon 
or by Ism s........................ oro “ O " O
d) Nosr podey or piogrom 
ot school or work........... lOQ " O '* 0
o| Cfmngo In Ids sHuodon 
log. morknl sisluo. 
omptoymont. moving 
homo, e t c .) ...................... '* o >*o « 0
f) Adsleo or support of 
hooNh prefosslowslls) . . ’•O " O ’» 0
g U slfh o lp  or mutuel old 
group (og. AA. weight 
WHchors)........................ " O »o » '0
h| Cfhor poopio ooldng 
on oiom plo...................... ” 0 “ O « 0
OChongoo In ooelol 
sohroo............................... “ O " O " O
pConuooralol products 
or sorvleoo...................... “ O “ O »o
kfProyororsplrltusI 
guldoneo............................ " O “ O " O
0 4 . Coooldotlog dm kooMi topics mo*so dli riiiood lo i 
dOMllMMofeo. Is dmio onytMng you Intsnd to dmngo
(DO HOT READ, UARK A U  THAT APPLY)
IPNOBE; Anyttring olooT)
""O NoOdng
0 * 0  Inctosos oxofdso, sports or physksl sedvfty
0 * 0  LooowoigM
" O  Chongo dot or soling hsUio
ooQ  Qud sffloMng/iodueo amount sfflokod
" O  Roduc# drugrnmdeoOon uso
0^ 0  Drtnk loss alcohol
" O  Msnogs or roduco Mood prosouro
" O  Msnogs or roduco cholsolsrol
' ° 0  loom to msnogs or roduco stroos
"O  Chongs phyoicsl onvlronfflont
" O  Rocoho modtoal trootnont
"O  ChsngssonmlbohSMlor or roduco dsit at STD’s
' * 0  knprew dontd hygiono
" O  Odisr cspoeoy;
SECTION R: 
CLASSnCATION QUESTIONS
mi. Nosr 0 fssr gonoioi qossdsns. 
Whoi lo yoor pootol oodoT
'O  Don’t know
m2. WhoilodmMghoslgrodoorlosololodseodomyowhoso
stioodod or osor complotsd? (UARK ONLY ONE)
" O  Noschooing
” 0  Somo 






“ O Sonm 
" O  Cemptsiod
'"O Othsr oducodon or training
') UNvsrslty 
{ (og. B.A.. M.A., Ph.D.| 
J  or Mocimr's codage
Consmunlly codogo. 
tsehnkol codogo,
CEQEP or nurao’s  IrsMng.
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n .  W M toH w•m and yMT • (  yaur MUT*|i»l I I Ym







do yau apMfe Moal •Han at I
RS. laadWma M a o #  lajoamy a l M  ar o d M  yraup i
To
» YOU
(ACCEPT UULnPLE RESPÔMSES, 0 0  MOT PflOBQ
0 * 0  EngMi 
“ O Ffondi 
" O  Seenwi 
“ O kWi 
“ O Oamian 





! ■■■■■■■■■■ 1 1 11
M . m m  10 yaar o m n l  
'O  «agiaffiaw  




aiaiNal MBiatT Ara yaa.
R7. Are there any eW d w iu n d er l s  years etdoldUfUiiln  
ymirhi
•O Y(
S yaara aid or ioooT ' O
•  to 11 yooro old? C ]
12 to 14 yooro oM? * □
» 0  No
Ri. W hotloyoarhool lOloNo f lh o lo lo l l  
dodoedon ? dfoo tho total hmu ahold
s2eAoe ®'0—
ttOAOOT “ O -
S%%? 0*0-
IMOO? "O
WAOO _  




armera « 0 - >
MOAoe? "O—
or moro? “ 0- »






"O  No ncoma 
“ O Don? know
SECTION 8: DATA SHAfUNQ AOREEMENT
S I . S ta tistics Canada la conducting tills dunoyJolRtlywItliHoallh and  W oHaroCanaila 
and th# provincial mlnlaNy roaponalMa 1er haaHh pramotlon In Albarta. Tiw  
Information coNaclad ariH bo kapt confidintlal and uaod only for Madatlcal purpoaaa.
DO YOU AGREE TO SHARE YOUR ANSWERS WITH THESE MINISTRIES?
YES 'O NO * 0
THANK YOU 
VERY MUCH FOR YOUR ASSISTANCE!
1 0 0
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
APPENDIX C-4
SELECTION CRITERIA FOR PARTICIPANTS 
Each potential participant was given a copy of the Health Promotion Survey to read and become 
familiar with the document. At a later date a research assistant contacted the potential participant 
by telephone and completes the survey. Using the Health Promotion Survey, along with previous 
research outlining diseases associated with mtDNA deletions, smoking definitions from the 
World Health Organization and guidelines for determining levels of physical activity from 
Statistics Canada, the research assistant selected each participant based on the following criteria.
1. Three (3) or four (4) generations
a. Maternal line (females for the first three [3] generations)
2. Can include one or more members of the same generation (e.g. twins) based on position 
within the generation
3. Can be from any geographic location
4. Can be from any nationality or race
5. Must not be suffering from any known diseases Y
6. Must not be participating in any high endurance physical activity on a regular basis!
*FMajor illnesses as defined in the literature and which would have a direct relationship with 
mitochondrial DNA (mtDNA) deletion.
[Physical activity as mentioned in the literature ” , referring to activity that exceeds 10 hrs per 
week also excluding professional athletes. Moderate leisure-time physical activity refers to 
reporting physical activities requiring at least medium energy expenditure (i.e., at least 1.5 
kilocalories per day, based on the duration and independently established energy demand of the 
activity) and reporting activities at least 12 times per month, where the duration of each session is 
at least IS min. Only recreational activities are considered for this measure (for example, 
physical activities at work or while commuting to and from work is not included).
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For the purposes of the study, smoking was defined as follows: Non-smokers as mentioned in the 
literature is someone who, at the time of the survey, does not smoke at all. A non-smoker can 
be divided further into three categories.
B1. Ex-smokers are people who were formerly daily smokers but currently do not smoke at
all.
B2. Never smokers are those who have never smoked at all, or have never been daily smokers
and have smoked less than 100 cigarettes in their lifetime.
B3. Ex-occasional are formerly occasional, but never daily, smokers and who smoked more
than 100 cigarettes in their lifetime and who does not now smoke at all.
1 0 2
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